AllerGen NCE Inc. is hosted at McMaster University, Hamilton, Ontario, Canada.

AllerGen NCE Inc. is supported by the Government of Canada through the Networks of Centres of Excellence (NCE) program.

Created in 1989, the NCE program is a joint initiative of the Natural Sciences and Engineering Research Council, the Social Sciences and Humanities Research Council, the Canadian Institutes of Health Research and Industry Canada.

AllerGen NCE Inc.
McMaster University
Michael G. DeGroote Centre for Learning & Discovery
1280 Main Street West, Room 3120
Hamilton, ON L8S 4K1

Telephone: (905) 525-9140 ext. 26502
Fax: (905) 524-0611
E-mail: info@allergen-nce.ca

www.allergen-nce.ca
## Table of Contents

Corporate Profile ......................................................................................................................................................... 3
2013-2014 At-a-Glance .................................................................................................................................................. 3
AllerGen’s Vision ............................................................................................................................................................ 3
AllerGen’s Mission .......................................................................................................................................................... 3

Message from the Board Chair and Scientific Director .................................................................................................. 4

2013-2014 Impacts ........................................................................................................................................................... 7

AllerGen’s Integrated Research Program ...................................................................................................................... 13

Research Highlights ....................................................................................................................................................... 17

Network Partners, Collaborators and Knowledge Users .................................................................................................. 23

International Partnerships ................................................................................................................................................ 25

Knowledge and Technology Exchange and Exploitation (KTEE) ................................................................................... 29

Knowledge Mobilization .................................................................................................................................................. 29

Commercialization ........................................................................................................................................................... 32

Tomorrow’s Leaders: AllerGen’s Highly Qualified Personnel (HQP) ........................................................................... 35

Financial Overview ......................................................................................................................................................... 47

Network Participants ....................................................................................................................................................... 49

AllerGen Board of Directors ........................................................................................................................................ 53

AllerGen Committees ....................................................................................................................................................... 55

AllerGen Administrative Centre Team ............................................................................................................................. 56

AllerGen Fast Facts, 2013-2014 ..................................................................................................................................... 57
Asthma and allergies have a profound impact on both individual and economic health: these illnesses cost the Canadian economy over $15 billion per year and are a leading cause of workplace absenteeism, diminished on-the-job productivity, hospital admissions and emergency department visits.
Corporate Profile

One in three Canadians is directly affected by allergic disease: nearly three million Canadians suffer from asthma; approximately 7.5% of the population self-reports at least one food allergy; and an estimated 21,000 Canadians die each year due to air pollution. The associated healthcare and economic burden reaches billions of dollars annually.

AllerGen NCE Inc. (AllerGen), the Allergy, Genes and Environment Network, is a national research network established in 2004 by Industry Canada through the Networks of Centres of Excellence (NCE) program to address these challenges to the health and productivity of Canadians.

AllerGen unites Canada’s leading research and clinical care experts in allergic diseases and asthma with related industry and not-for-profit organizations. Working in transdisciplinary and multisectoral teams, and in partnership with organizations and stakeholders across sectors, AllerGen addresses gaps in knowledge and seizes opportunities to generate new preventive strategies, diagnostic tests, therapeutic approaches, medications, public policies and educational tools to reduce the morbidity, mortality and socioeconomic impacts of allergy, asthma, anaphylaxis and related immune diseases.

These teams are also training the next generation of researchers, innovators and clinician-scientists. Since its inception, AllerGen has provided education, training and capacity building opportunities to 1,227 trainees and new professionals, and disbursed $2.3 million in trainee awards, grants and fellowships.

2013-2014 At-a-Glance

354 Trainees and young professionals, research associates and technicians
136 Partner organizations across academia, industry, not-for-profit and government
97 Full-time equivalent Network participants
93 Network investigators
47 Active research projects and strategic initiatives

AllerGen’s Vision

To create an enduring network of allergy and immune disease experts whose discovery and development efforts contribute to reducing the impact of allergic and related immune diseases nationally and globally.

AllerGen’s Mission

To catalyze and support discovery, development, networking, capacity building, commercialization and knowledge translation to reduce the morbidity, mortality and socioeconomic burden of allergy, asthma and anaphylaxis for the benefit of Canadians and the global community.
Message from the Board Chair and Scientific Director

As AllerGen approaches its final NCE mid-term review in September 2015, we remain focused on ensuring that the Network’s research investments translate into better health and an improved quality of life for Canadians living with allergic disease. We achieve this through the development of innovative education and training opportunities, improved clinical strategies, and new tools and technologies that generate sustainable Canadian jobs and productivity for the long term.

Throughout the past year, our research teams continued to identify opportunities to further integrate existing research projects and to refine legacy and sustainability strategies to ensure the Network’s impact extends well beyond its final year of NCE funding in 2019.

Our Legacy Projects continue to yield a wealth of data for researchers around the globe. As the youngest children participating in the Canadian Healthy Infant Longitudinal Development (CHILD) Study approach their second birthday, this birth cohort now offers the largest pool of infant microbiome data in the world. To date, the CHILD Study has supported seven substudies and has released 13,000 biological samples for analysis by researchers studying the early-life development of asthma, allergy and other chronic non-communicable diseases, including diabetes, obesity, hypertension and cardiovascular disease.

A five-year operating grant, awarded to the CHILD Study in March 2014 by the Canadian Institutes of Health Research (CIHR) Institute of Circulatory and Respiratory Health, will allow CHILD researchers to expand their efforts to investigate how selected environmental factors affect allergies and asthma in children with different genetic backgrounds, as reflected in their Genetic Risk Scores.

The AllerGen Clinical Investigator Collaborative (CIC) has expanded to add severe asthma and allergic rhinitis to its existing expertise in conducting Phase II clinical trials in allergic asthma. This broadened capacity is allowing biotechnology and pharmaceutical companies to evaluate potential new therapeutic molecules affecting allergic diseases in both the upper and lower airways.

Knowledge from the Canadian Food Allergy Strategic Team (CanFAST) projects continues to contribute to improved clinical management of food allergies and to identify food safety thresholds that inform public health standards, regulations and food industry guidelines. The launch of the synergistic GET-FACTS: Genetics, Environment and Therapies: Food Allergy Clinical Tolerance Studies initiative earlier this year will assist CanFAST to transition from knowledge discovery to knowledge translation, and to catalyze the development of a national food allergy strategy to improve the lives of Canadians living with food allergies and anaphylaxis.

AllerGen’s Legacy Projects are supported by ground-breaking work in the Gene-Environment Interactions, Biomarkers and Bioinformatics, and Patients, Policy and Public Health Enabling Platforms. In 2014, Dr. Michael Brauer, a Principal Investigator in the Gene-Environment Interactions platform, was recognized for his contributions toward improving the lives of Canadians suffering from asthma and allergies with two Asthma Society of Canada awards: the inaugural Bastable-Potts Asthma Research Prize and a For Life and Breath Innovation Award.

Over the past year, we have continued to welcome new investigators and mentors to the Network, and we have identified personalized health and bioinformatics/data integration as Network-wide initiatives that will provide a framework for future investment and application.
Our mandate to place the next generation of leaders in the field of asthma and allergy is being fulfilled as several more of our former trainees have “come of age” as new faculty members at Canadian universities. Since 2005, 47 AllerGen trainees have accepted academic appointments.

Our success is bolstered by the strength of our strategic, collaborative partnerships with other organizations both in Canada and abroad. This year, the Network secured its fifth international Memorandum of Understanding (MOU) through an agreement with The University of Queensland in Australia. AllerGen trainees have already benefitted by eagerly seizing upon new networking and research exchange opportunities with this world-class partner.

In November 2013, a much-needed asthma clinic opened in El Salvador’s National Lung Hospital. The “Clinica del Asma: Dr. Dean Befus”—named after AllerGen Principal Investigator Dr. Dean Befus, who spearheaded the initiative to help establish the new facility—is already making a difference. Support from AllerGen, made possible by an NCE International Partnerships Initiative grant awarded in 2007, was essential in enabling Dr. Befus and his colleagues at the Alberta Asthma Centre to forge international partnerships and to secure an MOU with the country’s Ministry of Health.

AllerGen has also taken a leadership role in advancing international efforts to tackle the rising burden of chronic, non-communicable diseases, which now pose a significant threat to global health. Network investigators Drs Jeff Brook, Anita Kozyrskyj and Tim Takaro presented at the 3rd Worldwide Universities Network (WUN) International Inflammation Network (In-FLAME) Annual Workshop in Cape Town, South Africa (March 30–31, 2014) to further our collective understanding of the early-life determinants of immune development and inflammation.

As we close the year, we extend our sincere congratulations and appreciation to the Board of Directors, the Research Management Committee and our many advisory committee members for their ongoing commitment and contributions to the Network.

In particular, we wish to thank Drs Richard Hegele, Bernard Prigent and Elinor Wilson, who completed terms on the Board of Directors, for their valuable contributions. We are delighted to welcome Dr. Mark Lundie and Dr. Harissios Vliagoftis as new members of the AllerGen Board of Directors.

AllerGen’s investigators, trainees, committee members, mentors, ASNPN executive members, national and global collaborators, stakeholder organizations and healthcare providers have been critical to the success of this Network. We thank them for their ongoing support and dedication to the goal of reducing the burden of allergic disease in Canada.

Dr. Howard Bergman,
MD, FCFP, FRCP(C)
Chair,
AllerGen Board of Directors,
AllerGen NCE Inc.

Dr. Judah Denburg,
MD, FRCP(C)
Scientific Director and CEO,
AllerGen NCE Inc.
What obligation do researchers have to return samples—and any unexpected findings from them—to patients and their families? Should patients have access to the results of experiments that use their specimens? Should patients give unlimited consent for the use of their samples?
Understanding public attitudes towards biobanking

The collection of biological samples for research use is called biobanking, and in 2009 *Time Magazine* flagged it as one of the top-ten ideas that is changing the world.

The practice began decades ago with small, university-based biobanks set up for specific research needs. Today, governments, research centres and other institutions manage their own biobank repositories, storing increasingly sophisticated specimens and information about the people who provided them. Several countries, Canada among them, have set up population-wide biobanks. AllerGen investigator Timothy Caulfield, a University of Alberta law professor and Canada Research Chair in Health Law and Policy, is concerned with the complex ethical issues associated with biobanking. He is exploring such questions as: What obligation do researchers have to return samples—and any unexpected findings from them—to patients and their families? Should patients have access to the results of experiments that use their specimens? Should patients give unlimited consent for the use of their samples? What happens to the personal information that is shared?

“I consider biobanking one of the greatest challenges in research ethics, not just nationally but throughout the world,” says Professor Caulfield.

As part of an AllerGen-supported project analyzing the legal and ethical dimensions of allergy and asthma research, Professor Caulfield is increasing our understanding of public attitudes towards biobanking and is contributing toward the development of ethical frameworks and policies to guide the practice.

In 2012, his research team polled over 1,200 Albertans, asking them about trust, consent, withdrawal of consent, access to data, and ownership of material. They also asked about a relatively new aspect of biobanking: commercialization. The results revealed differing opinions on a number of issues. A slim majority of respondents (52%) are willing to provide “broad consent,” meaning unconditional permission for researchers to repeatedly use their samples, while close to one in five (18%) would prefer to be consulted each time a sample is used. The remainder (30%) would like to have a say in how their samples are
used. Further, 44% of respondents felt specimens donated for research purposes belonged to the research institution, 26% thought specimens belonged to the individual donor, 23% thought the researcher retained ownership, and seven percent thought the research funder did.

On the topic of trust, however, most respondents agreed. “People have a lot of trust in university researchers, but their level of trust declines when industry is involved,” says Professor Caulfield.

Professor Caulfield and his team also undertook a comprehensive analysis of the international literature on broad versus informed consent for biobanking. From an analysis of 593 articles, they learned that, like Canadians, people in other countries do not agree on questions of consent.

“It’s not that we need public consensus to develop sound research policies,” he says. We do, however, “need to understand how the public feels so we can prepare for future controversies.”

Several academic papers have emerged from Professor Caulfield’s work. Most recently, in March 2014, the Journal of Law and the Biosciences published “A review of the key issues associated with the commercialization of biobanks.”

In another AllerGen-funded initiative, Professor Caulfield will investigate how the scientific community views these issues, especially the pressure to commercialize. With a handle on both the scientific and public views of biobanking, Professor Caulfield aims to contribute to the creation of ethical and enforceable biobanking guidelines and policies that will accelerate science, patient care and public health in Canada.

**Helping asthma patients breathe easier in El Salvador**

In November 2013, a much-needed asthma clinic opened in El Salvador—the smallest and most densely populated nation in Central America. The “Clínica del Asma: Dr. Dean Befus” is named after the AllerGen investigator who spearheaded the establishment of this new facility adjacent to the Dr. José Antonio Saldaña National Hospital in the country’s capital, San Salvador.

Dr. Befus, a professor of pulmonary medicine at the University of Alberta and Director of the Alberta Asthma Centre (AAC), is well aware of the significant asthma problem in El Salvador. “It’s a poor country by world health standards, and lung disease is especially prevalent there,” says Dr. Befus. “Some of the major issues are burning wood and other biofuels for cooking, and smoke in the kitchen. When you add limited access to asthma medications, it’s hardly surprising that so many of the country’s inhabitants suffer from uncontrolled asthma.”

In 2007, AllerGen received $828,000 from the Networks of Centres of Excellence (NCE) International Partnership Initiative (IPI) program to partner with international groups to reduce the global impact of allergies and other immune diseases. Dr. Befus’s proposal to improve asthma care in El Salvador was one of five AllerGen projects to receive IPI funding.

A partnership with the International Union Against Tuberculosis and Lung Disease (the Union)—an aid organization known for bringing medications to low-income populations—was a
centre of the program, and Dr. Befus and his AAC colleagues brokered a Memorandum of Understanding between the University of Alberta and the Salvadoran Ministry of Health.

In addition to facilitating access to low-cost asthma medications, Dr. Befus’s team designed an educational program to help asthma patients properly use their medications and avoid behaviour that exacerbates the condition. A well-known Salvadoran artist created many of the illustrations used in the educational tools, enhancing their cultural relevance.

The AAC team also trained local health providers to diagnose and treat asthma in line with best international practices. A Salvadoran physician and nurse were invited to Canada for three months of intensive education in asthma diagnosis, drug therapies and patient management, including the use of asthma education programs.

Alberta Health Services donated refurbished equipment to the clinic, including a plethysmograph or “body box”—a sealed chamber the size of a small telephone booth to measure lung capacity—facilitating more accurate diagnoses of asthma and other lung diseases.

Although only 250 square feet in size, Dr. Befus believes that “the clinic’s impact is big because of the expertise it houses.” The project is also expanding beyond the clinic’s walls, with Salvadoran health promoters sharing what they learn about asthma prevention and care with the wider community. “The plan is to disseminate this knowledge throughout society, from community hospitals to public health centres, schools and sports teams.”

The clinic team tests its new lung function machine.
AllerGen’s Canadian Healthy Infant Longitudinal Development (CHILD) Study has received a five-year operating grant, valued at over $1 million, from the Canadian Institutes of Health Research (CIHR) Institute of Circulatory and Respiratory Health. The CHILD Study application was ranked highest among 65 proposals reviewed by the Respiratory committee. The award will allow CHILD researchers to further explore how selected environmental factors to which children are exposed during pregnancy and in the first five years of life affect allergies and asthma in children with different genetic backgrounds, as reflected in their Genetic Risk Scores.

The CHILD Study has recruited over 3,600 pregnant mothers and is carefully assessing each child and its respective environment by collecting detailed housing, dietary and socioeconomic information, dust from homes, and biological samples such as breast milk, blood from parents and children, and children’s urine, feces and nasal secretions.

This landmark birth cohort study has already amassed a wealth of data: as of March 31, 2014,
almost 13,000 biological samples had been released for analysis. By 2017, the project will have collected more than 500,000 questionnaire responses and over 600,000 biological samples that will be available to scientists for decades.

To date, 10 peer-reviewed papers directly related to the CHILD Study have been published and over 60 abstracts based on CHILD Study data have been presented at scientific meetings around the world. Five new papers have been submitted for publication and many more are in preparation.

Early findings have already received international attention. In a March 2013 article published by the Canadian Medical Association Journal (CMAJ), CHILD Study researchers reported that three- to four-month-old babies born by elective cesarean section had a relative lack of a type of gut bacteria found in babies delivered vaginally. The study also found that formula-fed babies had differences in their gut bacteria compared to those who were strictly or partially breastfed.

In follow-up studies, researchers found that babies born by elective cesarean section still had differences in their gut bacteria at one year of age compared to babies born vaginally, but the difference was reduced if they were breast fed. Another analysis of data from the one-year-olds suggested that partial and extended breastfeeding influences the gut microbiome to protect against early childhood overweight.

Now that the oldest children in the study are five years old and the youngest are approaching their second birthday, researchers are asking: “What happens next in terms of health and disease outcomes?”

To tackle this question, CHILD Study researchers are using the data to examine many potential effects on health, including the impacts of: the infant microbiome, household phthalate exposure, maternal stress and anxiety, maternal and infant diet, living with pets, numbers of siblings, environmental exposures in and outside the home, and medication—especially antibiotic use—on the development of childhood allergies and asthma.

The results of these investigations may influence everything from building codes and household purchasing behaviours to decisions about childbirth and delivery, diet, breastfeeding, cleaning products used in homes, owning a family pet, and dealing with stress.
Throughout the year, our research teams have continued to identify opportunities to further integrate existing research projects and to refine legacy and sustainability strategies to ensure the Network’s impact extends well beyond its final year of NCE funding in 2019.
Helping Canadians address the challenges of living with asthma and allergic disease is at the core of AllerGen’s integrated research program. Led by internationally recognized Canadian researchers with expertise across a wide range of disciplines, the Network’s 47 active research projects and strategic initiatives employ multidisciplinary, cross-sectoral approaches to accelerate the development of new diagnostic tests, better medications, accessible patient education tools and effective public policies relevant to allergic disease.

Through strong partnerships, AllerGen leveraged its research investments to generate an additional $8.8 million in cash and in-kind support from partner and stakeholder organizations over the year—a leveraging ratio of 1:1.58.
The Canadian Healthy Infant Longitudinal Development (CHILD) Study

Research Leader:
Dr. Malcolm Sears, Professor,
Division of Respirology,
Department of Medicine,
McMaster University

Strategic Focus:
• a national birth cohort study following over 3,300 Canadian children from pre-birth to age five
• collects immunological, physiological and genetic data; dietary, housing and socio-economic information
• studies the impacts of genetics and the early-childhood environment on the development of asthma and allergies
• provides a platform to study the root causes of other chronic, non-communicable inflammatory diseases, including obesity, diabetes and cardiovascular disease
• involves over 40 investigators from 30 disciplines

The Clinical Investigator Collaborative (CIC)

Research Leaders:
Dr. Paul O’Byrne, Professor and Chair,
Department of Medicine,
McMaster University
Dr. Parameswaran Nair, Associate Professor,
Division of Respirology,
Department of Medicine,
McMaster University
Dr. Anne Ellis, Associate Professor,
Department of Biomedical and Molecular Sciences, Queen’s University

Strategic Focus:
• a multicentre, Canadian-based Phase II clinical trials group
• evaluates promising new treatments for the treatment of allergic diseases in the upper and lower airways
• fast-tracks early-stage potential drug candidates for allergic asthma, severe asthma and allergic rhinitis

The Canadian Food Allergy Strategic Team (CanFAST)

Research Leaders:
Jean Marshall, Professor and Head of Microbiology and Immunology,
Dalhousie University
Ann Clarke, Professor,
Division of Rheumatology,
Department of Medicine,
University of Calgary

Strategic Focus:
• a highly innovative, nationally networked research team studying food allergy and anaphylaxis
• contributes to our understanding of the origins, causes, prevalence and treatment of food allergy
• informs the development of improved diagnostic and treatment strategies, education programs, public health measures and public policy for the management of food allergy and anaphylaxis
Gene-Environment Interactions
Research Leaders:
Dr. Andrew Sandford, Associate Professor, Department of Medicine, The University of British Columbia
Dr. Jeffrey Brook, Senior Scientist, Air Quality Research Branch, Environment Canada; Assistant Professor, Division of Occupational & Environmental Health, Dalla Lana School of Public Health, University of Toronto

Strategic Focus:
• a collection of national and international teams working to apply genetic and environmental research innovation and new knowledge on “nature and nurture”
• focuses on genetic, environmental and epigenetic research
• aims to discover novel therapies and diagnostics, and facilitate the development of public health interventions and policies in the areas of asthma and allergies

Biomarkers and Bioinformatics
Research Leaders:
Dr. Kelly McNagny, Professor, Department of Medical Genetics, The University of British Columbia
Dr. Dean Befus, Professor, Division of Pulmonary Medicine, Department of Medicine, University of Alberta
Dr. John Gordon, Professor, Division of Respirology, Department of Medicine, University of Saskatchewan

Strategic Focus:
• an integrated, world-leading systems-biology approach to the discovery, development and commercialization of diagnostic tests and treatments for asthma and allergies
• focuses on predicting disease susceptibility, enabling early diagnosis, discriminating disease subtypes, monitoring disease prevention and drug response, and identifying novel therapeutic targets
• facilitates biomarker identification and analyses

Patients, Policy and Public Health
Research Leader:
Dr. Allan Becker, Professor and Head, Section of Allergy & Clinical Immunology, Department of Pediatrics and Child Health, University of Manitoba

Strategic Focus:
• a platform integrating interdisciplinary expertise to focus on the translation of AllerGen research that has policy, ethical, legal and/or social implications
• focuses on knowledge translation and knowledge mobilization to leverage the Network’s research expertise to generate new knowledge, products and services
• aims to inform public policy, public health practices, patient and health professional outreach, and educational disease management tools
REEGLE uses biological samples from AllerGen’s CHILD Study, the environmental exposure laboratories at UBC and the University of Toronto, and data from the Allergic Rhinitis Clinical Investigator Collaborative (AR-CIC). Samples from 145 babies participating in the CHILD Study and 120 tissue samples from subjects studied at Dr. Carlsten’s Air Pollution Exposure Laboratory at UBC are currently being analyzed.
Pan-Canadian team explores the epigenetics of allergic disease

AllerGen’s new epigenetics study is taking a closer look at how environmental exposures in early life can regulate the activity of genes relevant to the development of allergic diseases and asthma.

The project, called Rapid Environmental Effects on Genes: the Lens of Epigenetics (REEGLE), aims to determine if exposure to common allergens such as diesel exhaust, particulate matter and pollen affects DNA methylation patterns, and to test for an association between such exposures and risk of allergic disease.

The project is led by Dr. Michael Kobor, an associate professor in the Department of Medical Genetics at The University of British Columbia (UBC), with support from co-Principal Investigator and respiratory disease expert Dr. Chris Carlsten (UBC), and Drs Stuart Turvey (UBC), Anne Ellis (Queen’s University) and Frances Silverman (University of Toronto).

In DNA methylation, a specific chemical modification called a methyl group is added to the DNA backbone. If methylation occurs in a particular region of a gene, the gene function may be altered without affecting the underlying DNA.

“Any gene can have its activity regulated, in part by DNA methylation,” says Dr. Kobor. “DNA methylation acts like a dimmer control on a light switch that allows the light to be turned on and off, or dialled up and down. Once methylation has occurred, its impact can persist for a very long time.”

REEGLE uses biological samples from AllerGen’s CHILD Study, the environmental exposure laboratories at UBC and the University of Toronto, and data from the Allergic Rhinitis Clinical Investigator Collaborative (AR-CIC). Samples from 145 babies participating in the CHILD Study and 120 tissue samples from subjects studied at Dr. Carlsten’s Air Pollution Exposure Laboratory at UBC are currently being analyzed.

“REEGLE is a great example of how interdisciplinary research can really make a difference. The project is catalyzing the development of a pan-Canadian network of clinicians and scientists focused on the environmental regulation of allergic disease in children,” says Dr. Kobor. “Eventually, this team hopes to integrate sociological data—information about maternal socioeconomic status, mental health, and reported stress—collected as part of the CHILD Study, into this project.”

Improving asthma outcomes with air pollution research

An estimated 21,000 Canadians die each year due to air pollution—nearly nine times more than are killed in car accidents, according to an October 2013 Canadian Medical Association Journal (CMAJ) commentary by AllerGen investigator Dr. Michael Brauer and co-authors Dr. Conor Reynolds and Dr. Perry Hystad.

Their commentary links traffic-related air pollution to negative effects on health, and estimates that about 10 million Canadians, or one-third of the population, live close enough to highways or major urban roads to be at risk for pollution-related health problems, including asthma.

Dr. Brauer, a professor in the School of Population and Public Health at The University of British Columbia (UBC), and other AllerGen researchers at UBC, the University of Alberta and the University of Manitoba, have contributed to a body of ground-breaking research into traffic-related air pollution and its relationship to asthma in adults and children.

In February 2013, investigators involved with
Oral immunotherapy holds promise for milk allergic children

AllerGen researchers from five Canadian hospitals are working together to develop an effective and safe protocol for the treatment of cow’s milk allergy with oral immunotherapy (OIT).

Cow’s milk allergy—the most common food-related allergy in children—is frequently associated with severe allergic reactions and anaphylaxis. Treatment is based on strict avoidance, which may lead to nutritional deficiencies in growing children and is difficult to adhere to due to the widespread use of dairy products in Canadian foods.

OIT is a method of desensitizing the immune system by gradually exposing patients to incremental doses of a food allergen over time until tolerance is achieved. Led by Dr. Bruce Mazer and Dr. Moshe Ben-Shoshan at McGill University, the cow’s milk OIT project involves immunologists, clinicians, dietitians, biostatisticians and epidemiologists from the McGill University Health Centre, McMaster Health Sciences Center, the University of Alberta Health Sciences Centre, Dalhousie University, the IWK Health Centre—and soon, The University of British Columbia.

In the study, 34 children with milk allergy are being treated with incremental doses of milk until a predefined dose (200 mL), or the maximum dose a patient can tolerate without experiencing symptoms, is reached.

The research aims to develop an effective OIT protocol for milk allergy, determine the time following completion of therapy that subjects remain desensitized, and improve our understanding of the immunological changes that accompany successful OIT.

The outcomes—a refined methodology for administering milk OIT and a better understanding of which patients it will work for—will have a profound effect on the quality of life of allergic children and their caregivers, including parents, schools and childcare institutions.

This AllerGen study has contributed to the creation of GET-FACTS: Genetics, Environment and Therapies: Food Allergy Clinical Tolerance Studies—a project that combines components of population genetics, immunology, clinical medicine and sociocultural analyses to study the nature of food allergies.
In June 2013, GET-FACTS was awarded a five-year operating grant from the CIHR Institute of Nutrition, Metabolism and Diabetes. The award, valued at almost $2 million, will allow AllerGen investigators and collaborators to study the genetic and environmental factors influencing allergy and tolerance, investigate the role of microbial contamination in immunological tolerance and sensitivity to foods, and search for novel biomarkers of clinical allergy and tolerance in existing Canadian therapeutic trials.

**First prospective anaphylaxis study recruits 1,000 participants**

AllerGen’s Cross-Canada Anaphylaxis REgistry (C-CARE)—the first-ever prospective study on anaphylaxis—has recruited over 1,000 participants and is set to expand across the country.

C-CARE identifies cases of anaphylaxis through reports from “first responders,” including ambulance paramedics, emergency department staff and allergists. If a patient is willing to be included in the study, information about the episode, including symptoms, possible triggers for the reaction and how the anaphylaxis was managed, is entered into the registry’s database.

Now in its fourth year, C-CARE is led by AllerGen investigator Dr. Moshe Ben-Shoshan, a pediatric...
Dr. Ben-Shoshan says C-CARE will help researchers to assess the rate, triggers and management of anaphylaxis across the country. “As more results become available, physicians across the globe will be able to see that the registry provides important data,” he says. “Likely, they will want to examine what is happening in their own centres and compare their results to Canada.”

C-CARE currently recruits participants from centres in Quebec and British Columbia, and is set to expand into Ontario, Manitoba, Alberta and Newfoundland by 2015.

Health Canada has donated $50,000 to support the expanded registry and will use C-CARE results to evaluate the role of health policies, particularly those related to food labelling, in the prevention of anaphylaxis.

In September 2013, findings from the study’s first year were published in the Journal of Allergy and Clinical Immunology. The study revealed that among 168 children with anaphylaxis admitted to the Montreal Children’s Hospital, food triggered 84.5% of their reactions; 50% of milk- and peanut-induced reactions were attributable to inadvertent exposure to a known allergen; and epinephrine was under-used in treatment.
An article about the first C-CARE findings in adults has recently been accepted for publication. By comparing pediatric and adult populations and by following participants over the long term, Dr. Ben-Shoshan believes that C-CARE will provide the first reliable estimate of anaphylaxis rates in Canada and open the door to new ways of preventing and treating the condition.

**Expanded Clinical Investigator Collaborative tests new drugs for asthma and allergies**

Since 2005, AllerGen’s Clinical Investigator Collaborative (CIC)—a multicentre, Phase II clinical trials consortium—has created 40 jobs in the healthcare and private sectors, conducted more than 20 clinical trials and attracted over $23 million in partner funding, representing an AllerGen-to-industry investment ratio of one-to-seven.

With the addition of severe asthma (SA) and allergic rhinitis (AR) to its existing expertise in allergic asthma (AA), the CIC offers biotechnology and pharmaceutical companies an opportunity to evaluate promising new drug molecules for the potential treatment of allergic diseases in both the upper and lower airways.

**AA-CIC:**
Led by AllerGen investigator Dr. Paul O’Byrne (McMaster University), the AA-CIC integrates six research sites in Canada and one site in Sweden.

In 2013-2014, the AA-CIC provided “proof-of-concept” for an effective antibody treatment for asthma and published breakthrough research findings in the *Journal of Allergy and Clinical Immunology* (JACI), the *New England Journal of Medicine* (NEJM) and *Science Translational Medicine*.

AA-CIC researchers have published 10 peer-reviewed manuscripts and 15 abstracts, and collaborated on numerous joint publications.

**SA-CIC:**
Led by AllerGen investigator Dr. Parameswaran Nair (McMaster University), the SA-CIC integrates six research sites across Canada.

Although only 5-10% of asthmatics suffer from severe asthma, the condition accounts for over 50% of the costs related to asthma care.

The SA-CIC has undertaken clinical trials with pharmaceutical partners (Novartis and Astra-Zeneca) to study the prednisone-sparing effects of biologic molecules in patients with severe atopic eosinophilic asthma. These collaborations have produced four manuscripts: two published and two in preparation. Further, three new industry partnerships are in development. Funding from CIHR, NSERC and the Grand Challenges Canada-Stars in Global Health program is allowing these researchers to develop and validate point-of-care biomarker tests with commercial potential.

**AR-CIC:**
Led by AllerGen investigator Dr. Anne Ellis (Queen’s University), with co-PI Dr. Helen Neighbour (McMaster University), the AR-CIC consists of five participating research sites across Canada.

The incidence of allergic rhinitis, or hay fever, is even higher than asthma, with a lifetime prevalence between 30-50% among Canadians.

The AR-CIC has secured a partnership with Adiga Life Sciences Inc., a Canadian biotechnology subsidiary of UK-based Circassia Ltd. The partnership will utilize the AR-CIC’s standardized operating protocols for nasal allergen challenge to measure biomarkers for a novel peptide-based immunotherapy treatment for cat and ragweed allergies, developed by AllerGen investigator Dr. Mark Larché at McMaster University.
This year, the Network secured its fifth international Memorandum of Understanding through an agreement with The University of Queensland. AllerGen trainees have already benefitted by eagerly seizing upon new networking and research exchange opportunities with this world-class partner.
Network Partners, Collaborators and Knowledge Users

**AllerGen magnifies the impact of its research** by leveraging resources and expertise with partners in the private, public and non-profit sectors. AllerGen’s partners play an integral role in shaping and enhancing research outcomes, and in facilitating the commercialization of Network technologies, products and services.

In 2013-2014, AllerGen worked with 136 partners, collaborators and knowledge users, engaging an average of 4.75 collaborators per research project.

**Partners, Collaborators and Knowledge Users (n=136)**

**Universities (n=44)**
- (25 Canadian, 19 International)
  - Acadia University
  - American University
  - Brock University
  - Charité - Universitätsmedizin Berlin
  - Dalhousie University
  - Harvard University
  - Indiana University
  - Karolinska Institute
  - Lakehead University
  - McGill University
  - McMaster University
  - Northwestern University
  - Queen’s University
  - Simon Fraser University
  - Southern Methodist University
  - Stanford University
  - The University of British Columbia
  - The University of New South Wales
  - The University of Queensland
  - The University of Western Australia
  - The University of Winnipeg
  - Université de Montréal
  - Université du Québec à Chicoutimi
  - Université Laval
  - University College Cork
  - University of Alberta
  - University of Calgary
  - University of Copenhagen
  - University of Groningen
  - University of Guelph
  - University of Manitoba
  - University of Nebraska
  - University of New Brunswick
  - University of Ottawa
  - University of Oxford
  - University of Saskatchewan
  - University of Sherbrooke
  - University of Toronto
  - University of Victoria
  - University of Waterloo
  - University of Wisconsin
  - Utrecht University
  - Western University
  - Yeshiva University

**Hospitals and Health Centres (n=11)**
- Centre hospitalier universitaire (CHU)
  - Saint-Justine, Montréal
  - Hôpital du Sacré-Cœur de Montréal, Montréal
- Hospital Nacional General de Neumología y Medicina Familiar “Dr. Antonio Saldaña,” San Salvador, El Salvador
- Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ), Québec City
- Kingston General Hospital, Kingston
- Montreal General Hospital, Montreal
- St. Joseph’s Healthcare, Hamilton
- St. Joseph’s Hospital, Toronto
- St. Michael’s Hospital, Toronto
- The Hospital for Sick Children, Toronto
- The McGill University Health Centre, Montreal

**Industry (n=34)**
- (29 Canadian, 5 International)
  - Adiga Life Sciences Inc.
  - AIM Therapeutics Inc.
  - AstraZeneca Canada Inc.
  - Axikin Pharmaceuticals Inc., USA
Boehringer Ingelheim (Canada) Ltd./Ltée
Carr-Gordon Limited
Charles Frankish Consulting
CHENOMX Inc.
CTI Life Sciences Fund
David Brener & Associates
Deborah Danoff Consulting
Elinor Wilson Consulting
GlaxoSmithKline Inc.
Kincora Innovation
Leap Learning Technologies Inc.
Lincoln Diagnostics Inc./ALK, USA
Lumira Capital
Maple Leaf Foods
Mark Bisby Consulting
Merck Canada Inc.
Neo Stem Inc., USA
Norlien Foundation
Northtaste Flavourings Ltd.
Novartis Pharma Canada Inc.
Ono Pharmaceuticals Co. Ltd., Japan
Oxford University Press
Pfizer Canada Inc.
Pro-Bio Associates
Roche Canada
Sanofi Pasteur Ltd.
Shoppers Drug Mart Corporation
Suzanne Tough Consulting
TEC Edmonton
TVM Capital

Federal Agencies (n=8)
Canadian Institutes of Health Research
Cancer Stem Cell Consortium
Compute Canada
Environment Canada
Health Canada
Natural Science and Engineering Research Council
Office of the Privacy Commissioner of Canada
Public Health Agency of Canada

Provincial Agencies (n=7)
Alberta Health Services
Alberta Innovates
Fonds de recherche du Québec
Healthy Child Manitoba
Michael Smith Foundation for Health Research
Ontario Ministry of Health and Long-Term Care
Province of Nova Scotia

Non-Profit, Networks and Professional Associations (n=26)
Agriculture and Food Development Authority, Ireland
Alberta Asthma Centre
Allergy/Asthma Information Association (AAIA)
Anaphylaxis Canada
Association Québécoise des Allergies Alimentaires (AQAA)
Asthma Society of Canada
Canadian Lung Association/Canadian Thoracic Society
Canadian Network for Respiratory Care
Canadian Society of Allergy and Clinical Immunology
Centre for Drug Research and Development (CDRD)
Centre of Excellence for Prevention of Organ Failure (PROOF Centre)
Childhood Asthma Foundation
Children’s Hospital Foundation of Manitoba
Dairy Farmers of Canada
EMBO, Germany
European Respiratory Society, Switzerland
Family Physician Airways Group of Canada
Grand Challenges Canada
Immune Tolerance Network, USA
Montreal Children’s Hospital Foundation
National Institutes of Health, USA
Ontario Lung Association
Parker B. Francis Research Fellowship Program, USA
Stem Cell Network
The Hospital for Sick Children Foundation
The Sandbox Project

Research Institutes (n=6)
Alberta Centre for Child, Family and Community Research
Centre de recherche du Centre hospitalier de l’Université de Montréal (CHUM)
James Hogg Research Centre
Helmholtz Zentrum München, Germany
Munich Allergy Research Center (MARC), Germany
St. John’s Research Institute, India
International Partnerships

AllerGen continues to cultivate national and international partnerships that enrich training and skill acquisition opportunities for AllerGen students, new professionals and Network researchers. In January 2014, AllerGen signed a Memorandum of Understanding (MOU) with The University of Queensland’s Faculty of Medicine and Biomedical Sciences in Queensland, Australia. Collaborating centres at that university include the Lung & Allergy Research Centre (LARC), led by Professor John Upham, and the Queensland Children’s Medical Research Institute (QCMRI), headed by Professor Peter Sly.

The LARC pursues scientific research to understand the pathogenesis of asthma and other chronic pulmonary diseases, with particular interest in allergic inflammation and host defence against respiratory viral infections. The QCMRI is a child and adolescent health-focused research institute developed jointly by Children’s Health Services (Queensland Health), the Children’s Health Foundation (Queensland) and The University of Queensland.

This agreement represents AllerGen’s fifth international MOU based on a shared interest in promoting allergy, asthma and immune disease health research and related capacity building.

AllerGen also has long-standing agreements with the Centre for Allergy Research (CfA) at the Karolinska Institute in Sweden, The University of Newcastle in Australia, and three centres in Germany: the Allergie-Centrum-Charité at Charité-Universitätsmedizin Berlin; the Munich Allergy Research Center (MARC)-Technische Universität München (TUM); and Helmholtz Zentrum München-German Research Centre for Environmental Health.

In 2013-2014, several Network trainees undertook research visits to international partners. These experiences provided unique opportunities for research collaboration, knowledge exchange, networking and new skill development.

AllerGen-Australia exchanges pave the way for future collaboration

Dr. Jeremy Hirota, a Banting Postdoctoral Fellow, spent eight weeks working with Professor Philip Hansbro at The University of Newcastle’s Priority Research Centre for Asthma and Respiratory Diseases in New South Wales, Australia. During his stay, Dr. Hirota performed *in vitro* and *in vivo* experiments to study how uric acid—an antioxidant naturally produced by the body—may contribute to airway health and disease. He

“Ongoing collaborations with Professor Hansbro will allow for more impactful translational research studies that may improve the lives of Canadians, Australians, and indeed the general population throughout the world.”

Jeremy Hirota, PhD
The University of British Columbia
hopes to determine how the lung copes with environmental insults with the goal of informing public policy to improve air quality for Canadians.

Dr. Hirota is supervised by AllerGen investigator Dr. Chris Carlsten at The University of British Columbia (UBC). Dr. Carlsten, Professor Hansbro and he plan to seek collaborative grants to further their work on respiratory health.

Amrit Singh, a PhD candidate supervised by AllerGen investigator Dr. Scott Tebbutt at UBC’s James Hogg Research Centre, spent three months working at The University of Queensland’s Facility for Advanced Bioinformatics.

Mr. Singh worked with statistician Dr. Kim-Anh Le Cao to learn cutting-edge statistical methods addressing a range of study questions in high-dimensional biology, and to implement these methods using the statistical computing program “R.” Mr. Singh continues to collaborate regularly with Dr. Le Cao as this research progresses towards publication.

Food allergy research enhances understanding of parental decisions

Lianne Soller, a McGill University PhD candidate, spent six months working with Drs Audrey Dunn Galvin and Jonathan Hourihane and their teams in the School of Applied Psychology at University College Cork in Cork, Ireland.

Using the Food Allergy Quality of Life Questionnaire-Parent Form (FAQLO-PF), Ms. Soller investigated the role of information in parental decision-making when considering whether or not their child should undergo a food allergy challenge. Working with Dr. Dunn Galvin, a psychologist and expert in qualitative research, Ms. Soller enhanced her understanding of the psychology behind parental behaviours and decisions affecting food-allergic children.

Ms. Soller is supervised by AllerGen investigator Dr. Ann Clarke, University of Calgary. While in Cork, Ms. Soller collaborated with research teams at McGill University and the University of Calgary to develop a protocol to use the FAQLO-PF with children participating in Canadian food allergy registries. Using this protocol, the questionnaire was distributed to 1,445 patients involved in McGill University’s peanut, sesame, and seafood allergy registries. Research collaborators Drs Edmond

“Replicating this study in Canada will allow an improved understanding of how Canadian parents make treatment decisions for their food-allergic children. This knowledge could lead to changes in healthcare policies related to food allergy.”

Lianne Soller, PhD (c)
McGill University
Chan and Alex Lyttle at The University of British Columbia will analyze the data in 2015 to measure quality-of-life indicators among children with food allergies.

**Laboratory internship fuels research interest**

Laura Zuccaro completed a two-month research internship at the Karolinska Institute (KI) in Stockholm, Sweden. Ms. Zuccaro worked under the supervision of AllerGen collaborator Professor Sven-Erik Dahlén, and Anna James and Mikael Adner, members of his research group, to examine the expression of bitter taste (TAS2R) receptors on human bronchial smooth muscle (hBSM) after stimulation with different cytokines and drugs.

Ms. Zuccaro holds a B.HSc. from McMaster University where she worked with AllerGen investigator Dr. Parameswaran Nair. Currently, she attends medical school at the University of Ottawa.

“Our research was presented at the 2014 American Thoracic Society conference and will generate future publications. My experience at the Karolinska Institute fuelled my desire to solve research problems for my future patients. I look forward to my medical training with this goal in mind.”

Laura Zuccaro, medical student

University of Ottawa

---

**Former ASNPN President chosen for international anaphylaxis research**

Dr. Jennifer Protudjer, an ASNPN past-President, received a postdoctoral fellowship to investigate anaphylaxis and the risk factors associated with severe allergic reactions from the Karolinska Institute’s Centre for Allergy Research (CfA). This new research initiative—funded through a donation from Karin and Sten Mörtstedt CBD Solutions AB—will study factors that precipitate anaphylactic reactions with the goal of improving diagnosis and developing new treatments. Dr. Protudjer’s research will examine the prognosis of food allergy from childhood through to adolescence.

The Karolinska Institute is a longstanding AllerGen partner and one of the world’s leading medical universities. Dr. Protudjer originally developed her relationships at the Institute during a six-week trainee exchange facilitated by AllerGen’s International Partnership Initiative, which aims to produce globally-engaged scientists in the fields of allergy and asthma.
In March 2014, AllerGen facilitated the development of a non-exclusive, non-revenue generating license agreement between the University of Alberta and Anaphylaxis Canada. AllerGen’s commercialization program, which helps Network researchers secure knowledge mobilization and commercialization opportunities for their research outcomes, facilitated the process.
AllerGen’s KTEE activities continue to advance the Network’s goal to bridge the gap between the research lab and “real life” for Canadian families, educators, healthcare providers and policymakers dealing with asthma and allergies. AllerGen invests in targeted, strategic knowledge mobilization and commercialization initiatives to improve the relevance, uptake and application of its research results by partner organizations, stakeholders and receptor communities across the country.

Knowledge Mobilization

AllerGen Success Stories

AllerGen has published and distributed seven issues of Success Stories to over 1,200 Network participants, partners and knowledge users. Written for Canadian families and healthcare providers, Success Stories offers those living and dealing with allergic conditions and related immune diseases practical information about the Network’s latest research results.

In addition to diverse topics in the areas of asthma and allergies, Success Stories, available in English and French, features the accomplishments of the Network’s Highly Qualified Personnel.

AllerGen and AQAA team up against food allergies

Food allergy and anaphylaxis are growing concerns for Canadians. In 2010, a nationwide AllerGen-supported study revealed that approximately 2.6 million Canadians, or 7.5% of the population, self-report suffering from at least one food allergy.

On November 9, 2013, AllerGen promoted awareness of food allergies and anaphylaxis, and shared highlights from the Network’s CanFAST research projects, at a food allergy fair hosted by the Quebec Food Allergy Association (AQAA).

The free, all-day event attracted over 2,000 participants and featured expert speakers, one-on-one...
mark World Immunology Day. The Cafés brought outstanding panels of Canadian clinicians and researchers into these communities to discuss advances in the fields of immunology and allergy. Both events featured expert presentations followed by interactive discussions, and displays of sponsor information and resource materials.

**Allergies—what can be done?** was held in Vancouver, BC, hosted by the Child & Family Research Institute and the CIHR Human Immunology Network, and co-sponsored by AllerGen NCE.

**Allergies—what are they all about?** was held in Montreal, QC, and co-sponsored by the McGill University Health Centre, Centre hospitalier de l’université de Montréal, the CIHR Human Immunology Network and AllerGen NCE.

AllerGen investigators Drs Moshe Ben-Shoshan and Yuka Asai from McGill University presented research on filaggrin gene mutation associations with peanut allergy and AllerGen’s C-CARE registry for tracking cases of anaphylaxis.

### 2013 Cafés Scientifiques mark World Immunology Day

AllerGen's Café Scientifique series travelled to Vancouver and Montreal on April 29, 2013, to consultations with allergists, interactive workshops, cooking demonstrations and sponsor displays at the Complexe Desjardins shopping mall in downtown Montreal.

The audience learns more about the management of allergies (Montreal, QC).

University Health Centre, Centre hospitalier de l’université de Montréal, the CIHR Human Immunology Network and AllerGen NCE.

Left to right: Diana Royce (Managing Director and COO, AllerGen), Dominique Seigneur (Director of Communications and Finance, AQAA) and Kim Wright (Manager of Communications and Knowledge Mobilization, AllerGen).

Dr. Stuart Turvey explains how asthma develops (Vancouver, BC).
Symposium participants discussed important lessons learned from the Western Australian anaphylaxis strategy; identified strategies, tactics and stakeholder groups essential for the development and implementation of a national asthma strategy; and discussed country- and culture-specific barriers facing coordinated asthma care and ways to overcome them.

The Symposium was a pre-conference event affiliated with the International Health Economics Association (IHEA) 9th World Congress on Health Economics.

Keynote speakers at the AllerGen symposium included:

- **Larry Lynd, PhD**, AllerGen investigator; Associate Director, Collaboration of Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, The University of British Columbia
- **Richard Loh, MD**, President, Australasian Society of Clinical Immunology and Allergy (ASCIA), Subiaco, Western Australia
- **Wendy Ungar, PhD**, AllerGen investigator; Senior Scientist, Child Health Evaluative Sciences, The Hospital for Sick Children

Is there any indication that improved asthma and allergy policy can enhance an individual’s quality of life and improve the health of nations?

In July 2013, AllerGen hosted an international group of academics, policymakers and health advocates for the 2nd International Symposium on the Economics of Asthma and Asthma Care in Sydney, Australia, to debate this question.

**The economics of asthma**

Asthma and allergies have a profound impact on both individual and economic health: these illnesses cost the Canadian economy over $15 billion per year and are a leading cause of workplace absenteeism, diminished on-the-job productivity, hospital admissions and emergency department visits.

**CHILD Study in the Media 2013-2014**

The 12th Annual Re$earch Money Conference, *Checking the Pulse of Canada’s Innovation Policies*, took place in Ottawa, ON, in April 2013.

AllerGen’s Managing Director and COO, Dr. Diana Royce, chaired a session called “Priorities for Action” featuring innovators from Aonix Advanced Materials Corporation and Innoventures Canada.
Commercialization
Online support a lifeline for kids with food allergies

For children and teens with severe food allergies, dealing with discrimination, missing out on activities with their peers, and finding support when they feel isolated and lonely can be everyday challenges.

A multi-site, multipartner project supported by AllerGen has led to the launch of Allergy Pals, an online mentorship program designed to provide peer support to children affected by food allergies.

Program materials were designed by an interdisciplinary project team led by Dr. Miriam Stewart, a professor of nursing at the University of Alberta, with research funding provided by AllerGen and Alberta Innovates-Health Solutions.

The team piloted the program among children (ages 7-11) and teens (ages 12-15) recruited from across the country. The sessions included interactive discussions, games and activities designed to promote communication, problem-solving, and support-seeking skills. Each group was led by a peer mentor (ages 13-25)—someone who knows what it’s like to live with severe allergies—and supported by a Health Support and Education Specialist.

Anaphylaxis Canada, one of the project’s collaborators, expressed interest in licensing the program to provide ongoing support to children and youth with food allergies.

In March 2014, AllerGen facilitated the development of a non-exclusive, non-revenue generating license agreement between the University of Alberta and Anaphylaxis Canada. AllerGen’s commercialization program, which helps Network researchers secure knowledge mobilization and commercialization opportunities for their research outcomes, facilitated the process.

“I was able to pursue intellectual property protection for this project with support and expertise provided by AllerGen and TEC Edmonton, which have been invaluable in finalizing this agreement with Anaphylaxis Canada,” says Dr. Stewart.

Kyle Dine, Anaphylaxis Canada’s youth project coordinator, believes the launch of Allergy Pals illustrates how academic research can be mobilized from the university setting to community organizations to Canadian households. “Allergy Pals is important to our communities as it empowers children to tell their own stories, share experiences and learn from each other while they make new friends,” says Dine.

AllerGen and Health Canada target phthalate exposure in Canadian children

In March 2014, AllerGen concluded its third research project in partnership with Health Canada to determine whether exposures to phthalate plasticizers during fetal development and infancy contribute to the burden of asthma in Canada.

Canadian children are continuously exposed to phthalates—chemicals used in the manufacture of an array of everyday household products, such as vinyl flooring, fragrances, plastic bottles and utensils, and personal care products such as shampoo. Phthalates can be absorbed orally or through the respiratory tract or skin, and may contribute to the development of health problems, including asthma and reproductive effects.

As part of the federal government’s Chemicals Management Plan (CMP)—co-managed by Environment Canada and Health Canada—Dr. Tim Takaro, a professor of Health Sciences at Simon Fraser University, led a trilogy of AllerGen studies over a five-year period.

The most recent study, “Phthalate Exposures in Canadian Children During the First Three Years of Life,” received over $500,000 in support from Health Canada from 2011 to 2014. The study measured
the presence of phthalates in more than 800 Canadian children and tracked changes in phthalate levels at 12 and 36 months of age, using data and information obtained as part of AllerGen’s CHILD Study. This group was a subset of CHILD Study subjects previously analyzed with phthalate measurements at three months of age.

The research also identified the sources of phthalates using questionnaires to estimate exposures from diet, consumer products, medications and the home environment. With support from Health Canada’s Indoor Air Contaminant Assessment Section, the project further aimed to determine if exposure to these pollutants makes children more vulnerable to respiratory illnesses, including asthma.

The study’s findings showed that by three months of age, over 99% of Canadian children have been exposed to at least one phthalate, with several more exposures occurring during the first three years of life. Since an asthma diagnosis cannot be definitively made until age five, the findings on the development of asthma are as yet inconclusive.

Together with results from two earlier studies, this AllerGen-Health Canada collaboration will contribute to the development of preventive policy measures, with potentially significant impacts on consumer product regulation and on the information available to parents as they make lifestyle and consumption choices with their children’s health in mind.

AllerGen partners with the Canadian Respiratory Research Network (CRRN)

On February 24, 2014, Minister of Health Rona Ambrose announced the launch of the Canadian Respiratory Research Network (CRRN)—a new pan-Canadian research network that will study chronic obstructive pulmonary disease (COPD) and asthma, which together affect almost 15% of Canadians.

Through advocacy, in-kind support, mentoring, program collaboration and thought leadership, AllerGen has supported the establishment of this new network, which brings together 50 investigators from 20 institutions across the country to address key knowledge gaps in respiratory health.

“The Canadian Respiratory Research Network is delighted to work closely with AllerGen to advance lung research and lung health for Canadians,” comments CRRN Director Dr. Shawn Aaron. “Our Networks share many common interests and expertise, and our collaboration has thus far been seamless and productive. We look forward to many years of synergistic scientific partnership with AllerGen.”

A number of AllerGen researchers provide leadership and expertise to the CRRN’s themed research platforms. Collaboration between CRRN investigators and AllerGen’s CHILD Study, involving five sites across Canada, will advance the exploration of environmental and gene-environment effects in childhood asthma. AllerGen research teams in the Clinical Investigator Collaborative (CIC), and in the Biomarkers and Bioinformatics, Gene-Environment Interactions and Knowledge Mobilization research platforms, are well positioned to participate in collaborative research initiatives with the CRRN.

Further, AllerGen is partnering with the CRRN, the Canadian Lung Association, the Heart and Stroke Foundation and others to invest in the Emerging Research Leaders Initiative (ERLI)—a grant program for early-career researchers in the areas of cardiovascular, cerebrovascular and/or respiratory health research.

Ongoing collaboration with CRRN’s research and training initiatives will leverage AllerGen’s existing capacity building programs and extend the reach of Canadian research results for the benefit of those living with respiratory disease in Canada and around the world.
Our mandate to place the next generation of leaders in the field of asthma and allergy is being fulfilled as several more of our former trainees have “come of age” as new faculty members at Canadian universities. Since 2005, 47 AllerGen trainees have accepted academic appointments.
Since 2005, AllerGen has provided education, training and capacity building opportunities to 1,227 Highly Qualified Personnel (HQP) and disbursed over $2.3 million in trainee awards and fellowships.

By assimilating students and young professionals into multidisciplinary and multisectoral research and clinical training environments at over 20 sites across Canada, AllerGen’s HQP training program creates value-added, capacity building opportunities that promote knowledge acquisition, national and international networking, and the development of professional skill sets that enhance employment opportunities for graduates.

AllerGen trainees graduate from the Network with unique experiences and are mature, connected and confident of their ability to strengthen Canada’s knowledge base, innovative capacity and workforce productivity.

**AllerGen Students and New Professionals Network (ASNPN)**

Founded in 2007 to foster networking, knowledge exchange and professional skill development, the ASNPN comprises trainees (undergraduate students to postdoctoral fellows), new professionals and research staff working in the fields of allergy and asthma research.

Led by ASNPN President Lianne Soller, a PhD candidate at McGill University, the elected ASNPN Leadership Committee provides advice to AllerGen’s Advanced Education and Training Opportunities Advisory Committee (AETOAC).

HQP working on AllerGen-funded projects are automatically enrolled as ASNPN members. Individuals not directly working on an AllerGen project may apply to become an ASNPN member and access the associated benefits. In 2013-2014, there were 354 ASNPN members: 278 HQP actively involved in Network research and 76 students/new professionals working in related research areas.

**AllerGen HQP by Level of Study**

- **Postdoctoral**: 31 (9%)
- **MD/Fellows-in-Training**: 12 (3%)
- **PhD**: 49 (13%)
- **Masters**: 38 (11%)
- **Medical School**: 7 (2%)
- **Undergraduates**: 34 (10%)
- **Research Associates and Technicians**: 183 (52%)

**Total**: 354
Investment in undergraduates: A foundation for future success

AllerGen’s investment in the next generation of allergic disease researchers and clinician-scientists begins at the undergraduate level. Undergraduate students are fully integrated into the Network’s HQP training program and provided with opportunities to train alongside established AllerGen investigators and research teams.

“AllerGen’s academic and professional training has elevated my experience above that of most undergraduate students pursuing research. My involvement with AllerGen has truly been a highlight of my undergraduate studies.”

Laura Feldman, B.Sc., 4th-year University of Toronto (The Hospital for Sick Children)

Opportunities available to AllerGen undergraduates include:

- Research experience and mentorship
- Summer Studentships
- Poster Competitions
- Travel Awards
- Research skills acquisition support
- Annual Trainee Symposium
- Capacity building workshops

Undergraduate Summer Studentships spark interest in research

In 2013, AllerGen funded 10 outstanding undergraduate students from seven Canadian universities and related research institutes to work alongside

<table>
<thead>
<tr>
<th>Institution</th>
<th>AllerGen Funding</th>
<th>Partner Funding</th>
<th>Total Award Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>McMaster University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richard Hae</td>
<td>$3,000</td>
<td>$3,000</td>
<td>$12,000</td>
</tr>
<tr>
<td>Ashley Yu</td>
<td>$3,000</td>
<td>$3,000</td>
<td></td>
</tr>
<tr>
<td>McGill University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>John Ren</td>
<td>$3,000</td>
<td>$3,000</td>
<td>$6,000</td>
</tr>
<tr>
<td>The Hospital for Sick Children</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laura Feldman</td>
<td>$3,000</td>
<td>$3,000</td>
<td>$12,000</td>
</tr>
<tr>
<td>Ayanna Boyce</td>
<td>$3,000</td>
<td>$3,000</td>
<td></td>
</tr>
<tr>
<td>The University of British Columbia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angie Lam</td>
<td>$3,000</td>
<td>$3,000</td>
<td>$6,000</td>
</tr>
<tr>
<td>University of Alberta</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Timothy Chung</td>
<td>$3,000</td>
<td>$3,000</td>
<td>$12,000</td>
</tr>
<tr>
<td>Ryan Persaud</td>
<td>$3,000</td>
<td>$3,000</td>
<td></td>
</tr>
<tr>
<td>University of Calgary</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abid Qureshi</td>
<td>$2,300</td>
<td>$2,300</td>
<td>$4,600</td>
</tr>
<tr>
<td>Université du Québec à Chicoutimi</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valérie Gagné-Ouellet</td>
<td>$3,000</td>
<td>$3,000</td>
<td>$6,000</td>
</tr>
<tr>
<td>Total</td>
<td>$29,300</td>
<td>$29,300</td>
<td>$58,600</td>
</tr>
</tbody>
</table>

These opportunities promote inquiry-based learning, scholarship and creative accomplishments to enrich the undergraduate academic experience and encourage students to pursue advanced degrees.
AllerGen investigators. For each studentship, AllerGen provided up to $3,000 in support, matched 1:1 by Canadian partner organizations for a total program award value of nearly $60,000.

The AllerGen Summer Studentships program aims to foster interest in allergic and related immune disease research among undergraduate students, leading to advanced studies and potentially a career in related research and/or clinical practice.

AllerGen’s Summer Studentships provide undergraduates with opportunities to acquire new laboratory techniques and skills, develop expertise with study designs and protocols, and handle and code large datasets. Students also develop soft skills, such as communications, critical thinking, problem solving, public speaking and time management.

**AllerGen trainees selected for Young Canadians Roundtable on Health**

AllerGen trainees **Timothy Chung** from the University of Toronto and **Ryan Persaud** from the University of Manitoba are among a select group of 17- to 26-year-olds chosen from across Canada for The Sandbox Project’s 2013 Young Canadians Roundtable on Health (YCRH).

The YCRH brings together motivated young Canadians from coast-to-coast-to-coast in order to make real change to the health prospects of children and youth. The group provides leadership in research, public debate and education on issues affecting the present and future health of Canadian youth, including injury prevention, mental health, growing healthy bodies and the environment.

Mr. Chung and Mr. Persaud both held AllerGen Summer Studentships in 2013. Mr. Chung worked with Dr. Brian Rowe at the University of Alberta on the management of acute asthma in an urban Emergency Medical Service. Under the supervision of Dr. Anita Kozyrskyj at the University of Alberta, Mr. Persaud’s research focused on the impact of perinatal infant antibiotic exposures on allergic outcomes in the Winnipeg cohort of AllerGen’s CHILD Study.

“**My AllerGen summer studentship helped me to achieve a better understanding of the rigorous process of scientific enquiry and confirmed my commitment to pursue a career as a clinician-scientist.**”

Abid Qureshi, B.Sc., 3rd-year University of Calgary
Students pitch research at Trainee Poster Competition

AllerGen’s annual Trainee Poster Competition places the Network’s student research “front and centre,” offering trainees the opportunity to showcase their work and receive feedback from leading clinicians and scientists. Since 2005, more than 350 trainee posters have been presented and adjudicated.

In 2013, AllerGen hosted its poster competition in partnership with the Canadian Society of Allergy and Clinical Immunology (CSACI) at the CSACI Annual Scientific Meeting from October 3-6 in Toronto, Ontario. The competition attracted more than 30 research posters on projects undertaken within the context of AllerGen’s Enabling Platforms, which include Gene-Environment Interactions; Biomarkers and Bioinformatics; and Patients, Policy and Public Health.

During the competition’s lightning round of oral presentations, trainees were allotted one minute to highlight their findings to a panel of 12 judges. During the poster viewing, trainees provided a 10-minute presentation of their research to a pair of judges.

Eight AllerGen trainees, including three undergraduate students, took top honours at the 2013 CSACI poster competition. The winners were:

**Gene-Environment Interactions:**
- **First Place**
  - Dr. Elinor Simons, University of Toronto
  - Supervised by Dr. Teresa To, The Hospital for Sick Children
- **Second Place**
  - Dr. Michelle North, Queen’s University
  - Supervised by Dr. Anne Ellis, Queen’s University
- **Honourable Mention**
  - Sami Shariff, University of Calgary
  - Supervised by Dr. Richard Leigh, University of Calgary

**Biomarkers and Bioinformatics:**
- **First Place**
  - Amrit Singh, The University of British Columbia
  - Supervised by Dr. Scott Tebbutt, The University of British Columbia
- **Second Place**
  - Claudia Hui, McMaster University
  - Supervised by Dr. Judah Denburg, McMaster University

“The CSACI/AllerGen meeting was a unique experience where I had the opportunity to present my research findings to both clinical and basic science researchers. I received very useful advice that I can take back and apply to my research.”

Amrit Singh, PhD (c), Experimental Medicine
The University of British Columbia
Canadian Medical Hall of Fame laureate inspires trainees

In May 2013, over 50 trainees from across Canada gathered in Montreal, Quebec, to enhance their career development at AllerGen’s 8th Annual Trainee Symposium.

The three-day symposium provided an ideal networking environment to foster new collaborations among trainees and young professionals who share interests in allergy and asthma research and clinical practice.

Dr. Phil Gold—a 2010 Canadian Medical Hall of Fame laureate known for his distinguished record of scientific achievement in immunology and cancer—delivered the Symposium’s opening address, providing trainees with advice on achieving success in research.

Dr. Gold is the Douglas G. Cameron Professor of Medicine and Professor, Departments of Physiology and Oncology at McGill University, and the Executive Director of the Clinical Research Centre of McGill University Health Centre’s Research Institute.

The Annual Trainee Symposium provides trainees and ASNPN members with unique professional development opportunities that go well beyond the type of training typically provided in the academic classroom or laboratory.

“Presenting my project alongside graduate students and postdoctoral fellows allowed me to explore options for the next steps in my education and to appreciate the scope and calibre of research being conducted by young Canadian scientists in the fields of allergies and asthma.”

Ayanna Boyce, Health Studies, 4th-year
University of Waterloo

Honourable Mention
Jenny Thiele, Queen’s University
Supervised by Dr. Anne Ellis, Queen’s University

Patients, Policy and Public Health:
First Place
Linda Warner, The University of British Columbia
Supervised by Dr. Stuart Turvey, The University of British Columbia

Second Place
Laura Feldman, University of Toronto
Supervised by Dr. Teresa To, The Hospital for Sick Children

Honourable Mention
Timothy Chung, University of Toronto
Supervised by Dr. Brian Rowe, University of Alberta

Undergraduate Honours:
Laura Feldman, University of Toronto
Supervised by Dr. Teresa To, The Hospital for Sick Children

Timothy Chung, University of Toronto
Supervised by Dr. Brian Rowe, University of Alberta

Ayanna Boyce, University of Waterloo
Supervised by Dr. Padmaja Subbarao, The Hospital for Sick Children
**AllerGen Travel Awards**

AllerGen’s Travel Awards Program supports attendance and participation in national and international conferences, symposia and workshops that are aligned with AllerGen’s mission and vision.

Travel awards provide Network trainees and investigators with unique opportunities for public speaking, networking, research collaboration, knowledge exchange, and skill acquisition and development.

**2013-2014 Travel Awards Program**

$74,000 AllerGen & Partner FUNDING

39 AWARDS

35 PARTICIPANTS

6 NATIONAL EVENTS

10 INTERNATIONAL EVENTS

**AllerGen trainees among an elite cadre of early-career researchers**

Drs **Meghan Azad** from the University of Alberta and **Jeremy Hirota** from The University of British Columbia were named Banting Postdoctoral Fellows in 2013. The fellowships are Canada’s most prestigious awards for postdoctoral research and place these AllerGen trainees among an elite group of Canadian researchers recognized for demonstrating excellence and leadership in their fields of study.

**Meghan Azad** studies the role of gut bacteria in childhood asthma and allergies. Dr. Azad’s research uses data and biological samples from AllerGen’s CHILD Study to investigate the impact of antibiotics and other environmental factors on infant gut microbiota and the subsequent development of allergic disease.

Dr. Azad holds a PhD in Biochemistry and Medical Genetics from the University of Manitoba. She joined the University of Alberta as a Killam Postdoctoral Fellow in 2011, under the supervision of AllerGen researcher Dr. Anita Kozyrskyj.

**Jeremy Hirota** focuses on understanding the contribution of environmental exposures to asthma development and exacerbations. Dr. Hirota examines how air pollution interacts with airway epithelial cells by collecting samples from subjects who have been exposed to diesel exhaust.

"Presenting my research at AllerGen’s Symposium on the Economics of Asthma in Sydney, Australia, allowed me to receive collaborative, constructive feedback from experienced researchers in my field. I gained experience defending my methods, fielding questions, and presenting to a large international audience."

**Lilla Roy, M.Sc (c), Pharmaceutical Sciences**

The University of British Columbia
Dr. Hirota completed his PhD at McMaster University, specializing in asthma, and is a post-doctoral fellow at The University of British Columbia under the supervision of AllerGen investigator Dr. Chris Carlsten.

Young engineer receives competitive leadership award

Natalia Mykhaylova, a PhD candidate in chemical engineering at the University of Toronto, received the Professor Douglas Reeve Leaders of Tomorrow Award in March 2014. This award recognizes graduate students in the Department of Chemical Engineering and Applied Chemistry who have shown the potential to become outstanding leaders. Natalia serves as a co-chair for the University's Leadership Education in Engineering: Graduate program (ILead:Grad), a role that has allowed her to support and mentor others developing their leadership skills.

Natalia is part of the AllerGen-funded Better Exposure Avoidance Measures (BEAM) research project that is developing inexpensive air-quality monitoring devices under the supervision of AllerGen investigator Dr. Greg Evans. These devices could eventually be mounted on utility poles, carried by individuals at risk for asthma or respiratory conditions, or placed in the homes of research participants to measure personal exposure to air pollution.

Abstract receives highest score at European conference

Elaine Fuertes was honoured at the 6th Annual European Public Health Conference in Brussels, Belgium, in November 2013. Her abstract, “Traffic-related air pollution as a risk factor for the development of childhood allergic diseases: the Traffic, Asthma and Genetics (TAG) project,” received the highest score, placing first out of 796 submitted abstracts.

In August 2013, Ms. Fuertes was the lead author on a paper publishing results from the TAG project in the Journal for Allergy and Clinical Immunology (JACI). The paper, titled “Childhood allergic rhinitis, traffic-related air pollution, and variability in the GSTP1, TNF, TLR2, and TLR4 genes: Results from the TAG Study,” reported on the potential link between traffic-related air pollution and allergic rhinitis.

Ms. Fuertes is a PhD candidate supervised by Drs Chris Carlsten and Michael Brauer at The University of British Columbia. She is completing an extended internship at the Helmholtz Zentrum München-German Research Centre for Environmental Health, under the guidance of Dr. Joachim Heinrich.

“Drs Azad and Hirota are exceptional early-career scientists who are making substantial contributions to our understanding of the genetic and environmental influences of allergy and asthma.”

Dr. Judah Denburg, Scientific Director and CEO AllerGen NCE Inc.
FRQS-partnered award recognizes allergic diseases research

Dr. Moshe Ben-Shoshan was awarded the 2013-2014 Fonds de recherche du Québec-Santé (FRQS)/AllerGen Clinical Research Scholars Career Award. The award, which recognizes outstanding young clinical investigators who wish to pursue research on allergic and related immune diseases, will further Dr. Ben-Shoshan’s work with the AllerGen-funded C-CARE study and allow him to study the environmental, genetic and socio-demographic factors associated with food allergies.

A former AllerGen trainee, Dr. Ben-Shoshan also received AllerGen’s inaugural Emerging Clinician-Scientist Fellowship in 2011. Dr. Ben-Shoshan is an assistant professor of pediatrics at McGill University, a physician in the Department of Allergy/Immunology at Montreal Children’s Hospital and a Principal Investigator with AllerGen’s Canadian Food Allergy Strategic Team (CanFAST).

AllerGen trainees receive ATS Abstract Scholarships

Drs Francesco Sava and Masatsugu Yamamoto were honoured with Environmental and Occupational Health scholarships at the 2013 American Thoracic Society (ATS) conference in Philadelphia, PA. The ATS awards a limited number of abstract scholarships annually. Drs Sava and Yamamoto completed postdoctoral training at The University of British Columbia, supervised by AllerGen investigator Dr. Chris Carlsten.

Dr. Francesco Sava, MD, M.Sc.
Abstract: Peripheral Blood DNA Methylation Changes Associated with Acute Diesel Exhaust Exposure in Asthmatics

Dr. Masatsugu Yamamoto, MD, PhD
Abstract: Controlled Human Exposure to Inhaled Diesel Exhaust Increases Circulating MiR-144, Which is Attenuated by Antioxidant Supplementation

HQP alumni embark on careers across diverse sectors

The NCE program aims to provide cross-disciplinary expertise and an enhanced skill set to increase the employability of its HQP. Since 2005, 149 AllerGen alumni have found employment with stakeholders across various sectors, including academia (48%), industry and the private sector (30%), provincial and federal governments (17%) and hospitals (5%).

In 2013-2014, over 40 AllerGen trainees secured employment—the highest single-year employment figure for HQP in the past decade. Examples of areas where these graduates are employed include:

Academia

Yuka Asai (MD, M.Sc.) joined the Division of Dermatology at Queen’s University in Kingston, ON. She also provides consultation services to the Kingston General Hospital and outpatient services at the Hotel Dieu Hospital. Dr. Asai is currently completing her PhD at McGill University under the supervision of AllerGen investigator Dr. Ann Clarke. Dr. Asai is a former member of the ASNPN Leadership Committee.

Elinor Simons (MD, M.Sc.) is an assistant professor/clinician scientist in the Section of Allergy, Department of Pediatrics and Child Health, at the University of Manitoba. Dr. Simons is currently in the final stages of completing her PhD at The Hospital for
Sick Children under the supervision of AllerGen investigator Dr. Teresa To. Dr. Simons is one of only a few population epidemiologists working in pediatrics in Canada.

Victoria Arrandale (PhD) is Senior Research Associate in the Occupational Cancer Research Centre at Cancer Care Ontario and an assistant professor in Occupational and Environmental Health at the University of Toronto’s Dalla Lana School of Public Health. Dr. Arrandale completed her PhD studies at the University of Toronto’s Gage Occupational & Environmental Health Unit under the supervision of AllerGen investigators Drs Frances Silverman and Linn Holness. Dr. Arrandale is a former member of the ASNPN Leadership Committee.

Clinical practice

Karine Issa El-Khoury (MD) is a practicing allergist and partner at the Clinique d’allergie et d’asthme de Montréal. Dr. Issa El-Khoury completed her allergy and clinical immunology training in pediatrics at McGill University.

Zainab Abdurrahman (MD) is a pediatric clinical immunologist and allergist at Kindercare Pediatrics in Toronto, ON. Dr. Abdurrahman is an assistant clinical professor (adjunct) in the Department of Pediatrics at McMaster University and also works at McMaster Children’s Hospital in Hamilton. Dr. Abdurrahman completed her subspecialty training in Clinical Immunology and Allergy at McMaster University where she worked with AllerGen investigator Dr. Susan Waserman on the AllerGen CanGoFAR team.

Government

Sri Chaudhuri (M.Sc.) works at the Ontario Ministry of the Environment. Ms. Chaudhuri trained in the Department of Chemical Engineering and Applied Chemistry at the University of Toronto under the supervision of AllerGen investigator Dr. Miriam Diamond.

Not-for-Profit

Kathleen McLean (MPH) is an Environmental Health Scientist at the British Columbia Centre for Disease Control. Prior to and during her graduate studies in Public Health at Simon Fraser University, Ms. McLean worked with AllerGen investigator Dr. Tim Takaro on projects measuring biomarkers of phthalate exposure in CHILD Study participants.

Farzian Aminuddin (MBA) is a business analyst at the Ontario Genomics Institute. Mr. Aminuddin
worked as a laboratory researcher at The University of British Columbia (UBC) James Hogg Research Centre with Dr. Andrew Sandford prior to pursuing his MBA at Simon Fraser University. He is a former member of the ASNPN Leadership Committee.

Industry

Marie-Josée Martel (PhD) was hired as the Director of Scientific Client Strategies at Xcenda in Palm Harbor, Florida. Dr. Martel completed her graduate training at the Université de Montréal under the supervision of AllerGen investigator Dr. Lucie Blais. Dr. Martel also serves as adjunct faculty at the Faculty of Pharmacy at the Université de Montréal.

Hospital

Lilla Roy (M.Sc.) is employed as a Clinical Research Project Coordinator at The Hospital for Sick Children’s Peter Gilgan Centre for Research & Learning. A registered nurse, Ms. Roy completed her Masters of Science in Pharmaceutical Sciences (epidemiology and health economics) at The University of British Columbia. She has worked with AllerGen investigator Dr. Larry Lynd on the Platform for Outcomes Research in Asthma and Allergy (PORTAL)—an AllerGen-funded research project.
A Snapshot of AllerGen HQP, 2013-2014

(n=354)

- Working on related research 76 (21.5%)
- Working on AllerGen research projects 278 (78.5%)

Female 242 (68%)
Male 112 (32%)

Canadian 321 (91%)
Foreign 33 (9%)

AllerGen HQP Graduates 2005-2014 (n=287)
Continuing education 102 (35.5%)

AllerGen HQP Employment by Sector 2009-2014 (n=149)
- Employed 149 (52%)

- Other or Unknown 36 (12.5%)
- Industry/Private Sector 45 (30%)
- Government 26 (17%)
- Hospitals: 7 (5%)
- University 71 (48%)

- Total 354 (100%)

Trainees, New Professionals, Research Associates and Technicians by Province

<table>
<thead>
<tr>
<th>Province</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ontario</td>
<td>110</td>
<td>31%</td>
</tr>
<tr>
<td>Alberta</td>
<td>85</td>
<td>24%</td>
</tr>
<tr>
<td>British Columbia</td>
<td>79</td>
<td>22%</td>
</tr>
<tr>
<td>Quebec</td>
<td>42</td>
<td>12%</td>
</tr>
<tr>
<td>Manitoba</td>
<td>28</td>
<td>8%</td>
</tr>
<tr>
<td>Saskatchewan</td>
<td>7</td>
<td>2%</td>
</tr>
<tr>
<td>Outside Canada</td>
<td>3</td>
<td>1%</td>
</tr>
</tbody>
</table>

Total 354 100%

Trainees, New Professionals, Research Associates and Technicians by University

<table>
<thead>
<tr>
<th>University</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>The University of British Columbia</td>
<td>75</td>
<td>21.2%</td>
</tr>
<tr>
<td>University of Alberta</td>
<td>51</td>
<td>14.5%</td>
</tr>
<tr>
<td>McMaster University</td>
<td>46</td>
<td>13.0%</td>
</tr>
<tr>
<td>Affiliated Institutions and Organizations</td>
<td>33</td>
<td>9.3%</td>
</tr>
<tr>
<td>University of Calgary</td>
<td>32</td>
<td>9.0%</td>
</tr>
<tr>
<td>University of Manitoba</td>
<td>27</td>
<td>7.6%</td>
</tr>
<tr>
<td>McGill University</td>
<td>21</td>
<td>5.9%</td>
</tr>
<tr>
<td>Queen’s University</td>
<td>17</td>
<td>4.8%</td>
</tr>
<tr>
<td>Université Laval</td>
<td>13</td>
<td>3.7%</td>
</tr>
<tr>
<td>University of Toronto</td>
<td>12</td>
<td>3.4%</td>
</tr>
<tr>
<td>University of Saskatchewan</td>
<td>7</td>
<td>2.0%</td>
</tr>
<tr>
<td>Simon Fraser University</td>
<td>4</td>
<td>1.2%</td>
</tr>
<tr>
<td>University of Waterloo</td>
<td>4</td>
<td>1.2%</td>
</tr>
<tr>
<td>Université de Montréal</td>
<td>3</td>
<td>0.8%</td>
</tr>
<tr>
<td>Université du Québec à Chicoutimi</td>
<td>3</td>
<td>0.8%</td>
</tr>
<tr>
<td>Outside Canada</td>
<td>3</td>
<td>0.8%</td>
</tr>
<tr>
<td>University of Guelph</td>
<td>1</td>
<td>0.3%</td>
</tr>
<tr>
<td>University of Winnipeg</td>
<td>1</td>
<td>0.3%</td>
</tr>
<tr>
<td>Western University</td>
<td>1</td>
<td>0.3%</td>
</tr>
</tbody>
</table>

Total 354 100%
Through strong partnerships, AllerGen leveraged its research investments to generate an additional $8.8 million in cash and in-kind support from partner and stakeholder organizations over the year — a leveraging ratio of 1:1.58.
**Financial Overview**

**AllerGen NCE Inc. Financial Summary 2013–2014**

### Revenues (Cash)

<table>
<thead>
<tr>
<th></th>
<th>2012-2013 (Year 8)</th>
<th>Percentage</th>
<th>2013-2014 (Year 9)</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCE Award</td>
<td>6,828,135</td>
<td>91.94%</td>
<td>5,604,865</td>
<td>91.09%</td>
</tr>
<tr>
<td>Non-NCE Funds</td>
<td>598,972</td>
<td>8.06%</td>
<td>548,538</td>
<td>8.91%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>7,427,107</td>
<td>100.00%</td>
<td>6,153,403</td>
<td>100.00%</td>
</tr>
</tbody>
</table>

### Expenditures (Cash)

<table>
<thead>
<tr>
<th></th>
<th>2012-2013 (Year 8)</th>
<th>Percentage</th>
<th>2013-2014 (Year 9)</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research Programs</td>
<td>4,639,700</td>
<td>74.66%</td>
<td>3,859,854</td>
<td>69.31%</td>
</tr>
<tr>
<td>Networking</td>
<td>27,314</td>
<td>0.44%</td>
<td>210,333</td>
<td>3.78%</td>
</tr>
<tr>
<td>Training</td>
<td>279,131</td>
<td>4.49%</td>
<td>315,373</td>
<td>5.66%</td>
</tr>
<tr>
<td>Communications</td>
<td>47,948</td>
<td>0.77%</td>
<td>71,088</td>
<td>1.28%</td>
</tr>
<tr>
<td>Administration</td>
<td>1,220,406</td>
<td>19.64%</td>
<td>1,112,484</td>
<td>19.98%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>6,214,500</td>
<td>100.00%</td>
<td>5,569,132</td>
<td>100.00%</td>
</tr>
</tbody>
</table>

Committed Amounts for Future Research

<table>
<thead>
<tr>
<th></th>
<th>2012-2013 (Year 8)</th>
<th>Percentage</th>
<th>2013-2014 (Year 9)</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCE</td>
<td>1,789,000</td>
<td></td>
<td>1,210,140</td>
<td></td>
</tr>
<tr>
<td>Non-NCE</td>
<td>1,302,607</td>
<td></td>
<td>584,271</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>6,214,500</td>
<td>100.00%</td>
<td>5,569,132</td>
<td>100.00%</td>
</tr>
</tbody>
</table>

### All Revenue Sources (Cash and In-Kind) 2013/14 NCE and Non-NCE (n=14,441,294)

<table>
<thead>
<tr>
<th>Source</th>
<th>Cash</th>
<th>In-Kind</th>
<th>Total</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCE (38.81%)</td>
<td>5,604,865</td>
<td>–</td>
<td>5,604,865</td>
<td>39.81%</td>
</tr>
<tr>
<td>Industry (24.49%)</td>
<td>3,000,259</td>
<td>536,182</td>
<td>3,536,441</td>
<td>24.49%</td>
</tr>
<tr>
<td>Hospital (12.58%)</td>
<td>300,000</td>
<td>1,516,000</td>
<td>1,816,000</td>
<td>12.58%</td>
</tr>
<tr>
<td>University (8.74%)</td>
<td>84,070</td>
<td>1,177,696</td>
<td>1,261,766</td>
<td>8.74%</td>
</tr>
<tr>
<td>Not-for-Profit (6.27%)</td>
<td>473,437</td>
<td>432,475</td>
<td>905,912</td>
<td>6.27%</td>
</tr>
<tr>
<td>Federal (3.63%)</td>
<td>50,000</td>
<td>474,725</td>
<td>524,725</td>
<td>3.63%</td>
</tr>
<tr>
<td>Other Sources (3.37%)</td>
<td>473,437</td>
<td>432,475</td>
<td>905,912</td>
<td>6.27%</td>
</tr>
<tr>
<td>Provincial (2.11%)</td>
<td>52,300</td>
<td>251,988</td>
<td>304,288</td>
<td>2.11%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$ 9,979,903</strong></td>
<td><strong>$ 4,461,391</strong></td>
<td><strong>$ 14,441,294</strong></td>
<td><strong>100%</strong></td>
</tr>
</tbody>
</table>

In 2013-14, AllerGen’s income from all sources (cash and in-kind) was $14,441,294. Of this amount, $5,604,865 was received as a base grant from the NCE program. For every dollar that AllerGen received from the NCE program, it leveraged an additional $1.58, resulting in an additional investment of $8,836,429 from the private, public and not-for-profit sectors.
Over the past year, we have continued to welcome new investigators and mentors to the Network and we have identified personalized health and bioinformatics/data integration as Network-wide initiatives that will provide a framework for future investment and application.
## Network Participants

### Investigators (n=93)

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edmond Chan</td>
<td>BC Children’s Hospital</td>
</tr>
<tr>
<td>Heather Castleden</td>
<td>Dalhousie University</td>
</tr>
<tr>
<td>Jean Marshall</td>
<td>Dalhousie University</td>
</tr>
<tr>
<td>Jeff Brook</td>
<td>Environment Canada</td>
</tr>
<tr>
<td>Sandy Kapur</td>
<td>Halifax Allergy &amp; Asthma Associates</td>
</tr>
<tr>
<td>Sébastien La Vieille</td>
<td>Health Canada</td>
</tr>
<tr>
<td>Cathy Gillespie</td>
<td>Health Science Centre Winnipeg</td>
</tr>
<tr>
<td>Wade Watson</td>
<td>IWK Health Centre</td>
</tr>
<tr>
<td>Diane Lougheed</td>
<td>Kingston General Hospital</td>
</tr>
<tr>
<td>Jeremy Scott</td>
<td>Lakehead University</td>
</tr>
<tr>
<td>Moshe Ben-Shoshan</td>
<td>McGill University</td>
</tr>
<tr>
<td>Lawrence Joseph</td>
<td>McGill University</td>
</tr>
<tr>
<td>James Martin</td>
<td>McGill University</td>
</tr>
<tr>
<td>Bruce Mazer</td>
<td>McGill University</td>
</tr>
<tr>
<td>Celia Greenwood</td>
<td>McGill University Health Centre</td>
</tr>
<tr>
<td>Ciriaco Piccirillo</td>
<td>McGill University Health Centre</td>
</tr>
<tr>
<td>Sonia Anand</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Judah Denburg</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Sarah Garside</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Gail Gauvreau</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Manel Jordana</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Paul Keith</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Anthony Levinson</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Joseph Macri</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Parameswaran Nair</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Helen Neighbour</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Paul O’Byrne</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Malcolm Sears</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Susan Waserman</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Carlo Marra</td>
<td>Memorial University</td>
</tr>
<tr>
<td>Anne Ellis</td>
<td>Queen’s University</td>
</tr>
<tr>
<td>Ryan Allen</td>
<td>Simon Fraser University</td>
</tr>
<tr>
<td>Fiona Brinkman</td>
<td>Simon Fraser University</td>
</tr>
<tr>
<td>Timothy Takaro</td>
<td>Simon Fraser University</td>
</tr>
<tr>
<td>Sharon Dell</td>
<td>The Hospital for Sick Children</td>
</tr>
<tr>
<td>Theo Moraes</td>
<td>The Hospital for Sick Children</td>
</tr>
<tr>
<td>Felix Ratjen</td>
<td>The Hospital for Sick Children</td>
</tr>
<tr>
<td>Sanja Stanojevic</td>
<td>The Hospital for Sick Children</td>
</tr>
<tr>
<td>Padmaja Subbarao</td>
<td>The Hospital for Sick Children</td>
</tr>
<tr>
<td>Wendy Ungar</td>
<td>The University of British Columbia</td>
</tr>
<tr>
<td>Michael Brauer</td>
<td>The University of British Columbia</td>
</tr>
<tr>
<td>Chris Carlsten</td>
<td>The University of British Columbia</td>
</tr>
<tr>
<td>Denise Daley</td>
<td>The University of British Columbia</td>
</tr>
<tr>
<td>Del Dorscheid</td>
<td>The University of British Columbia</td>
</tr>
<tr>
<td>Mark FitzGerald</td>
<td>The University of British Columbia</td>
</tr>
<tr>
<td>Michael Kabor</td>
<td>The University of British Columbia</td>
</tr>
<tr>
<td>Tobias Kollmann</td>
<td>The University of British Columbia</td>
</tr>
<tr>
<td>Larry Lynd</td>
<td>The University of British Columbia</td>
</tr>
<tr>
<td>Kelly McNagny</td>
<td>The University of British Columbia</td>
</tr>
<tr>
<td>Peter Paré</td>
<td>The University of British Columbia</td>
</tr>
<tr>
<td>Andrew Sanford</td>
<td>The University of British Columbia</td>
</tr>
<tr>
<td>Scott Tebbutt</td>
<td>The University of British Columbia</td>
</tr>
<tr>
<td>Stuart Turvey</td>
<td>The University of British Columbia</td>
</tr>
<tr>
<td>Catherine Lemière</td>
<td>The University of British Columbia</td>
</tr>
<tr>
<td>Catherine Laprise</td>
<td>The University of British Columbia</td>
</tr>
<tr>
<td>Louis-Philippe Boulet</td>
<td>Université de Montréal</td>
</tr>
<tr>
<td>Jamila Chakir</td>
<td>Université du Québec à Chicoutimi</td>
</tr>
<tr>
<td>Marie-Renée Blanchet</td>
<td>Université Laval</td>
</tr>
<tr>
<td>Dean Befus</td>
<td>Université Laval - IUCPQ</td>
</tr>
<tr>
<td>Stuart Carr</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Timothy Caulfield</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Catherine Field</td>
<td>University of Alberta</td>
</tr>
</tbody>
</table>
### Name
Malcolm King  
Anita Kozyrskyj  
Piush Mandhane  
Irvin Mayers  
Miriam Stewart  
Harissios Vliagoftis  
Tavis Campbell  
Ann Clarke  
Gerry Giesbrecht  
Bonnie Kaplan  
Richard Leigh  
Nicole Letourneau  
Katherine Wynne-Edwards  
Allan Becker  
Marni Brownell  
Mariette Chartier  
Kent HayGlass  
Jeffrey Masuda  
Darryl Adamko  
Don Cockcroft  
John Gordon  
Peter Hull  
Miriam Diamond  
Greg Evans  
Richard Hegele  
Wendy Lou  
James Scott  
Frances Silverman  
Peter Vadas  
Kathi Wilson  
Susan Elliott

### Affiliation
University of Alberta  
University of Alberta  
University of Alberta  
University of Alberta  
University of Alberta  
University of Alberta  
University of Calgary  
University of Calgary  
University of Calgary  
University of Calgary  
University of Calgary  
University of Calgary  
University of Calgary  
University of Calgary  
University of Calgary  
University of Manitoba  
University of Manitoba  
University of Manitoba  
University of Manitoba  
University of Saskatchewan  
University of Saskatchewan  
University of Saskatchewan  
University of Saskatchewan  
University of Saskatchewan  
University of Toronto  
University of Toronto  
University of Toronto  
University of Toronto  
University of Toronto  
University of Toronto  
University of Toronto  
University of Toronto  
University of Waterloo

### NCE Standard Agreement Signatories (n=33)
Centre de Recherche du CHUM  
Centre hospitalier universitaire (CHU) Saint-Justine  
Dalhousie University  
Helmholtz Zentrum München  
Hôpital du Sacré-Coeur de Montréal  
Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ)  
Karolinska Institute  
Lakehead University  
McGill University  
McGill University Health Centre  
McMaster University  
Queen’s University  
Simon Fraser University  
St. John’s Research Institute, India  
St. Joseph’s Healthcare, Hamilton  
The Hospital for Sick Children  
The University of British Columbia  
The University of Western Australia  
The University of Winnipeg  
Université de Montréal  
Université du Québec à Chicoutimi  
Université Laval  
University of Alberta  
University of Calgary  
University of Guelph  
University of Manitoba  
University of New Brunswick  
University of Ottawa  
University of Saskatchewan  
University of Sherbrooke  
University of Toronto  
University of Waterloo
HQP and Research Staff (n=354)

Shelley Abercromby  
Karim Abou-Moustafa  
Daniel Adams  
Omid Aghamirian  
Loubna Akhabir  
Kim Allan  
Sheka Aloyouni  
Mustafa Al-Saiedy  
Nelly Amenyogbe  
Vidyvanand Anaparti  
Yasmin Arfeen  
Jason Arnason  
Muhammad Asaduzzaman  
Yuka Asai  
Ghazal Assadian  
Susan Attridge  
Katrina Au  
Séverine Audusseau  
Hana Awad  
Jane Awawias  
Meghan Azad  
Jason Babu  
Bahar Bahrami  
Salma Bahreinian  
Jyoti Balhara  
Susan Balkovec  
Kendra Barrick  
Shirley Beauchamp  
Suzanne Beauin  
Pierrick Bedouch  
Philippe Bégin  
Emilie Bernatchez  
Mylène Bertrand  
Hilary Bews  
Litsa Blanis  
Marie-Ève Boulay  
John Bousfield  
Jodie Bousfield  
Katie Bowden  
Miranda Bowen  
Ayanna Boyce  
Julyanne Brassard  
Graeme Bredo  
Karina Breuer  
Sarah Bridgman  
May Brydges  
Sarah Burningham  
Bing Cai  
Maureen Campbell  
Francesca Cardwell  
Sylvie Carette  
Simone Chaboillez  
Michelle Chakraborti  
Sarah Charlesworth  
Mariette Chartier  
Wenjai Chen  
Roy Chen  
Carol Chen  
Joyce Chikuma  
Rishma Choohnedass  
Angela Chow  
Derek Chu  
Timothy Chung  
Laura Churchman  
Rachel Clifford  
Lisa Colizzi  
Caroline Conway  
Victoria Cook  
Marie-Ève Côté  
Melanie Courtot  
Fiona Cowley  
Melanie Cowley  
Rowena Cua  
Beth Davis  
Wojciech Davicki  
Carlo De Olim Rugginenti  
Phillip Deng  
Francine Deschesnes  
Marylin Desjardins  
Benny Dua  
Aimee Dubeau  
Curtis Dumonaceaux  
Joanne Duncan  
Stacey Dunn  
Judy Durocher  
Ann Eththiadiis  
George Ellis  
Caroline Ethier  
Kelsey Falk  
Laura Feldman  
Penelope Ferrie  
Catherine Field  
Mike Filia  
Nick Fishbane  
Jennifer Fitzpatrick  
Andrea Fong  
Amir Foroushani  
Annie-Pier Fortin  
Tosha Freitag  
Silvia Frias  
Elaine Fuertes  
Cathy Fugère  
Melissa Gabruck  
Myriam Gagné  
Valérie Gagné-Ouellet  
Jessica Galo  
Vivek Gandhi  
Tresa George  
Brenda Gervign  
Sagal Ghelle  
Deanna Gilbert  
Luisa Giles  
Matt Gold  
Susanna Goncharova  
Emma Goosey  
Susan Goruk  
Krista Gray  
Tara Grey  
Maja Grubisic  
Qingdong Guan  
Pampa Guha  
Annahita Hadioonzadeh  
Richard Hae  
Michelle Halbrich  
Mona Hamada  
Daniel Harrington  
Martha Hart  
Carrie Hartman  
Brenda Helpard  
Delia Heroux  
Angela Hillaby  
Jeremy Hirot  
Barnaby Hobsbawn  
Elana Hochstadder  
Kris Hong  
Ali Hosseini  
Doug Houibrook  
Karen Howie  
Milton Hu  
Henry Huang  
Magdalena Hudy  
Adam Hughes  
Claudia Hui  
Linda Hui  
Saiful Huq  
Karine Issa El-Khoury  
Kyla Jamieson  
Cheol-Heon Jeong  
Ruiwei Jiang  
Meaghan Jones  
Taruna Joshi  
Rose Kalu  
Cynthia Kanagaratham  
Neha Kanga  
Michael Kariwo  
Hessam Kashani  
Tosha Kells  
Amir Khakban  
Diva Khoury  
Katie Killorn  
Melanie Kjarsgaard  
Linda Knox  
Joshua Kong  
Tedd Konya  
Joyce Kum  
Erika Ladouceur  
Salma Lalji  
Angie Lah  
Chynace Lambalgen  
Kim Lambert  
Amanda Lau  
Flora Lau  
Lynda Lazosky  
Elizabeth Lee  
Diana Lefebvre
Duncan Lejtényi
Johanne Lepage
Claire Lepine
Marie Levesque
Bernard Lo
Raymond Lo
Ingrid Loewen
Mark Loewen
Jemma Loki-Vuzi
Steven Long
Martin Lopez
Katherine Lortie
Larisa Lotoski
Zihang Lu
Fiona Luke
Julie MacIsaac
Meaghan MacNutt
Crystal Malone
Steven Maltby
Robby Mamonluk
Jen Marisiane
Andrea Marrin
Mary Ann Mauro
Suzanne McCollum
Marcelo Menezes
Susan Menzies
Pascal Mercier
Rachel Meyer
Melody Miki
Christopher Mill
Jennifer Mill
Joanne Milot
Danielle Minor
Tima Mohammadi
Tae Chul Moon
Sem Moreno
Andréanne Morin
Gregory Moulliec
Manali Mukherjee
Natalia Mykhaylova
Drew Nahirney
Stephanie Nairn
David Ngan
Sergei Nikitenko
Michelle North
Dominik Nowak
Ma'en Obeidat
Caitlin Obminski
Megan O’Connor
Jennifer O’Hara
Andrew O’Keefe
Joseph Okeme
John Paul Oliveria
Adam Ollenberg
Tim Olynych
Vanessa Omana
Scott Orr
Hong Ouyang
Pipi Panaritis
Christopher Pascoe
Alicia Pavlowsk
Faye Pedersen
Miki Peer
Jonathan Pelikan
Ryan Persaud
Samantha Pollard
Julia Poole
Audrey Poon
Phaedra Propp
Jennifer Protudjer
Mandy Pui
Teresa Pun
Abid Qureshi
Katherine Radford
Tanvir Rahman
Felix Ratjen
Pia Reece
Shana Regush
John Ren
Christopher Rider
Nola Ries
Melinda Roberts
Elii Rosenberg
Roxanne Rousseax
Lila Roy
Jian Ruan
Shannon Russell
Min Hyung Ryu
Aabida Saferali
Scarlet Salas
Amandeep Sanai
Francesco Sava
Hind Sbhi
Tara Scime
Maggie Sebesta
Yokananth Sekar
Diane Semeniuk
Suharsh Shah
Greg Shand
Casey Shannon
Sami Shariff
Pawan Sharma
Leah Shaver
Christopher Shlofoon
Nami Shrestha
Noreen Sibanda
Elizabeth Simms
Elinor Simons
Amrit Singh
Gurpreet Singhera
Christopher Skappak
Sherri Smith
Steve Smith
Muriel Solignon
Mena Soliman
Lianne Soller
Mary Speck
Anastasia Sribnaia
Nutan Srivastava
Chris St. Laurent
Danielle St. Laurent
Lisa Steacy
Whitney Steber
William Stefura
Yvan St-Pierre
Darren Sutherland
Veronica Swystun
Marc Sze
Christina Taggart
Anthony Tam
Emery Tempest
Stephanie The
Jenny Thele
Leah Thomas
Tahira Tiwana
Abbey Torek
Danielle Tougas
Suzanne Traves
Christine Troskie
Penny Tryphonopoulos
Gina Tsai
Nicolette Tsao
Tambra Tufford
Julie Turmel
Elizabeth Turnbull
Claire Unruh
Bruce Urch
Linnea Veinotte
Jing Venevongsa
Hélène Villeneuve
Michelle Vine
Samuel Wadsworth
Heather Waldhauser
Terry Walker
Brandie Walker
Alethea Wallace
Tina Wang
Linda Warner
Stephanie Warner
Rick Watson
Lynele Watt
Carolyn Weiss
Beth Whalen
Michele Willits
Sze Wing Wong
Juliana Xie
Janet Xu
Masatsugu Yamamoto
Dong Yan
Bin Yang
Jasemine Yang
Yarden Yanishevsky
Madelaine Yona
Ashley Yu
Zafar Zafari
Lukic Zdravko
Xiaobei Zhang
Fay Zhu
Laura Zuccaro
AllerGen Board of Directors

Howard Bergman, MD, FRCP(C)
Montreal, QC
Chair

Mark Bisby, DPhil
Ottawa, ON
Vice-Chair

Douglas Barber, PhD
Hamilton, ON

Glenna Carr, ICD.D
Toronto, ON

Deborah Danoff, MD, FRCP(C)
Ottawa, ON

Patrick Deane, PhD
Hamilton, ON

Judah Denburg, MD, FRCP(C)
Hamilton, ON

Charles Frankish, MD, FRCP(C)
Ottawa, ON

Christine Hampson, PhD
Toronto, ON

Richard Hedges, MD, FRCP(C), PhD
Toronto, ON, to Nov 2013

Jean-François Leprince
Montreal, QC

Mark Lundie, PhD
Toronto, ON, From Feb 2014

Bernard Prigent, MD, MBA
Kirkland, QC, to Jan 2014

Lorne Tyrrell, OC, AOE, MD, PhD
Edmonton, AB

Harissios Vliagoftis, MD
Edmonton, AB, From Jan 2014

Elinor Wilson, PhD
Ottawa, ON

Lisa Drouillard
Ottawa, ON, ex officio

Diana Royce, EdD
Burlington, ON, ex officio

Lianne Soller, MSc
Montreal, QC
ex officio

Donald Stark, MD, FRCP(C)
Vancouver, BC
Board of Directors

Howard Bergman, MD, FRCP(C)  (Chair) Chair, Department of Family Medicine; Professor, Departments of Family Medicine, Medicine and Oncology; Dr. Joseph Kaufmann Professor of Geriatric Medicine, McGill University

Mark Bisby, DPhil  (Vice-Chair) Consultant

Douglas Barber, PhD  Distinguished Professor-in-Residence, Faculty of Engineering, McMaster University

Glenna Carr, ICD.D  President and CEO, Carr-Gordon Limited

Deborah Danoff, MD, FRCP(C)  Professor, University of Ottawa

Dan Kerr, MD  President and Vice-Chancellor, McMaster University

Patrick Deane, PhD  President and Vice-Chancellor, McMaster University

Judah Denburg, MD, FRCP(C)  Scientific Director and CEO, AllerGen NCE Inc.

Charles Frankish, MD, FRCP(C)  Allergist and Clinical Immunologist, Kanata Allergy Services

Christine Hampson, PhD  President and CEO, The Sandbox Project

Richard Hegele, MD, FRCP(C), PhD  Professor and Chair, Department of Laboratory Medicine & Pathobiology, University of Toronto; Chief, Department of Paediatric Laboratory Medicine, The Hospital for Sick Children (to November 2013)

Jean-François Leprince  Managing Partner, CTI Life Sciences Fund

Mark Lundie, PhD  Director, Medical Affairs, Rare Diseases, Pfizer Canada Inc. (from February 2014)

Bernard Prigent, MD, MBA  VP & Medical Director, Pfizer Canada Inc. (to January 2014)

Donald Stark, MD, FRCP(C)  Professor, Department of Medicine, The University of British Columbia

Lorne Tyrrell, QC, AOE, MD, PhD  Professor and CIHR/GSK Chair in Virology; Director, Li Ka Shing Institute of Virology, University of Alberta

Harissios Vliagoftis, MD  Associate Professor and Director, Division of Pulmonary Medicine, Department of Medicine, University of Alberta (from January 2014)

Elinor Wilson, PhD  Consultant

Lisa Drouillard, MA, ex-officio  Program Deputy Director, NCE Secretariat

Diana Royce, EdD, ex-officio  Managing Director and COO, AllerGen NCE Inc.

Lianne Soller, PhD (c), ex-officio  President, ASNPN; McGill University
AllerGen Committees

Research Management Committee (RMC) Membership
Judah Denburg, MD, FRCP(C) (Chair) Scientific Director and CEO, AllerGen NCE Inc.
Allan Becker MD, FRCP(C) Professor and Head, Section of Allergy & Clinical Immunology, Department of Pediatrics & Child Health, University of Manitoba
Jeff Brook, PhD Senior Scientist, Air Quality Research Branch, Environment Canada; Assistant Professor, Division of Occupational & Environmental Health, Dalla Lana School of Public Health, University of Toronto
Dean Befus, PhD Professor, Division of Pulmonary Medicine, Department of Medicine, University of Alberta
Tim Caulfield, LLM Professor, Faculty of Law and School of Public Health, and Research Director, Health Law Institute, University of Alberta; Canada Research Chair in Health Law and Policy; Senior Health Scholar, Alberta Heritage Foundation for Medical Research
Ann Clarke, MD Professor, Division of Rheumatology, Department of Medicine, University of Calgary
Terry Delovitch, PhD Professor Emeritus, Department of Microbiology & Immunology, University of Western Ontario
John Gordon, PhD Professor, Division of Respiratory Medicine, University of Saskatchewan
Jean Marshall, PhD Professor and Head, Department of Microbiology & Immunology, Dalhousie University
Kelly McNagny, PhD Professor, Department of Medical Genetics, The University of British Columbia
Paul O’Byrne, MD Professor and Chair, Department of Medicine, McMaster University
Mark Raizenne, SD Director General, Centre for Food-borne, Environmental and Zoonotic Infectious Diseases, Public Health Agency of Canada
Andrew Sandford, PhD Associate Professor, Department of Medicine, The University of British Columbia
Malcolm Sears, MB, ChB Professor, Division of Respirology, Department of Medicine, McMaster University

David Shindler, PhD President and CEO, Pro-Bio Associates
Stuart Turvey, MD Director, Clinical Research, Child & Family Research Institute; Associate Professor, Division of Infectious & Immunological Diseases, Department of Pediatrics, The University of British Columbia
Randall Yatscoff, PhD Executive Vice-President, TEC Edmonton
Lisa Drouillard, MA, ex-officio Program Deputy Director, NCE Secretariat
Pia Reece, PhD, ex-officio Vice-President, ASNPN; McMaster University
Diana Royce, EdD, ex-officio Managing Director and COO, AllerGen NCE Inc.

Network-Supported Intellectual Property (NSIP) Advisory Committee Membership
Diana Royce, EdD (Chair) Managing Director and COO, AllerGen NCE Inc.
Dean Befus, PhD Professor, Division of Pulmonary Medicine, Department of Medicine, University of Alberta
Thierry Bourgeois, MScA Adjoint au vice-recteur à la recherche et à la création et vice-rectorat à la création, Pavillon des Sciences de l’éducation, Université Laval
David Brener, PhD Principal, David Brener & Associates Inc.
Terry Delovitch, PhD Professor Emeritus, Department of Microbiology & Immunology, University of Western Ontario
Judah Denburg, MD, FRCP(C) Scientific Director and CEO, AllerGen NCE Inc.
Neal Lemon, PhD, MBA Technology Transfer Officer (Health Sciences), Industry Liaison Office, University of Saskatchewan (from December 2013)
Luc Marengère, PhD Managing Partner, TVM Capital
Kevin O’Brien Fehr, PhD Consultant
Brian Underdown, PhD Managing Director, Lumira Capital
Randall Yatscoff, PhD Executive Vice-President, TEC Edmonton
Arlene Yee, PhD Director, Industry Partnerships and Commercialization, The Hospital for Sick Children (to September 3, 2013)
Advanced Education and Training Opportunities Advisory Committee (AETOAC) Membership

Chris Mody, MD (Chair) Professor and Head, Department of Microbiology, Immunology & Infectious Diseases, University of Calgary
Fiona Brinkman, PhD Professor, Department of Molecular Biology & Biochemistry, Simon Fraser University
Thomas Issekutz, MD Professor and Head, Division of Immunology, Department of Pediatrics, Dalhousie University
Oxana Latycheva, PhD Manager, Clinical Health Systems Initiatives, Ontario Lung Association
Irvin Mayers, MD Professor, Division of Pulmonary Medicine, Department of Medicine, University of Alberta
Danuta Radzioch, PhD Professor, Department of Medicine, McGill University; Medical Scientist, Clinical Immunology, Montreal General Hospital
Lianne Soller, PhD (c) President, ASNPN; McGill University
Wendy Ungar, PhD Associate Professor, Health Policy, Management and Evaluation, University of Toronto; Senior Scientist, Child Health Evaluative Sciences, The Hospital for Sick Children
Richard Warrington, MBBS, PhD Professor, Department of Medicine, University of Manitoba
Susan Waserman, MD Professor, Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University
Diana Royce, EdD Managing Director and COO, AllerGen NCE Inc.

AllerGen Students and New Professionals Network (ASPNPN) Executive

Lianne Soller, PhD (c) President (McGill University)
Pia Reece, PhD Vice-President (McMaster University)
Meghan Azad, PhD Events Director (University of Alberta)
Elaine Fuertes, PhD (c) Secretary/Treasurer (The University of British Columbia) (to June 2013)
Luisa Giles, PhD Communications Director (The University of British Columbia)
Jeremy Hirota, PhD Regional Director: Pacific (The University of British Columbia) (to June 2013)
Amrit Singh, PhD (c) Regional Director: Pacific (The University of British Columbia) (from June 2013)
Sami Sharrif, M.Sc. (c) Regional Director: Central (University of Calgary) (from June 2013)
Claudia Hui, PhD (c) Regional Director: Ontario (McMaster University)
Stephanie Nairn, PhD (c) Regional Director: Quebec/Atlantic (McGill University)
Carlo de Olim Rugginenti, M.Sc. (c) Member-at-Large (Université de Montréal)

AllerGen Administrative Centre Team

Judah Denburg, MD Scientific Director and CEO
Diana Royce, EdD Managing Director and COO
José Mangles Manager, Research and Partnerships
Kim Wright Manager, Communications and Knowledge Mobilization
Carol Ridsdale Financial Officer
Michelle Harkness HQP and Events Coordinator
April O’Connell Administrative Coordinator, Research and Partnerships
Marshall Beck Administrative Coordinator, Communication and Knowledge Mobilization
AllerGen FAST FACTS
2013-2014

NCE : Non-NCE investment leverage ratio
1 : 1.58

Research Investments

Legacy Projects

Enabling Platforms

Strategic Initiatives

12

24

11

B&B

GxE

PPP

7

9

8

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP

CanFAST

CIC

CanFAST

B&G

GxE

PPP